[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Hologic, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":377},{"warningLetters":4,"total":376},[5,31,53,77,97,121,142,164,186,206,224,246,262,283,303,320,340,359],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1093,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-18T05:00:00Z\">12\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhologic-inc-698214-12182024\">Hologic, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stephen MacMillan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FPresident\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hologic, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>250 Campus Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marlborough\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>01752-3020\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Steve.MacMillan@hologic.com\"> Steve.MacMillan@hologic.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 698214\u003C\u002Fp>\u003Cp>December 18, 2024\u003C\u002Fp>\u003Cp>Dear Mr. MacMillan:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Marlborough, MA on July 30, 2024, through September 24, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class II implantable radiographic markers, such as your BioZorb product line. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Adam Gorzeman, Senior Director BSH Quality, dated October 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We are aware that Hologic has made the decision to discontinue the manufacture of the BioZorb product line. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). You did not implement your Design Control Procedures, including Design Control SOP0018 dated 01\u002F31\u002F2017, Product Development Procedure ENG0100 dated 03\u002F19\u002F2024 and User Needs and Intended Use Statement Procedure ENG-0100-02 dated 04\u002F21\u002F2022. Specifically:\u003C\u002Fp>\u003Cp>a. You failed to establish design inputs to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). The design history file for the BioZorb medical device product family:\u003Cbr>• Did not identify the intended patient population, nor did it address intended anatomy types, nor the surgical requirements such as the appropriate placement and fixation of the device, nor the appropriate depth of the implant into the soft tissue.\u003Cbr>• Did not include a requirement related to how in-vivo radiation treatments can impact the performance of the device and the ability of the device to resorb into the patient’s body.\u003Cbr>• Did not define the length of time for when the spacer material would be completely resorbed.\u003C\u002Fp>\u003Cp>b. You failed to verify your device design to confirm that the design output meets the design input requirements, as required by 21CFR 820.30(f).\u003Cbr>• Your firm does not have any verification testing to demonstrate that the bioabsorbable spacer material (poly lactic acid) is absorbed by the body. Your Design Description Document DDD-0001 dated August 22, 2017, includes a user requirement that the BioZorb medical device spacer material is resorbable into soft body tissue. Your verification testing report, VER-10394 dated June 27, 2022, only documents the inherent viscosity profile of the spacer during in-vitro degradation and does not provide sufficient data to support the claim that that spacer material is absorbed by the body. Your firm received complaints and filed Medical Device Reports regarding devices requiring explant and a lack of resorption, including Hologic Complaint Report CPT-01345922 which stated that the device failed to dissolve for almost five (5) years.\u003C\u002Fp>\u003Cp>c. You failed to validate your device design to ensure that devices conform to defined user\u002Fpatient needs and intended uses, as required by 21 CFR 820.30(g).\u003Cbr>• Your Design Validation studies performed under Marker Simulated Use Test Report TR-004 Rev P dated 08\u002F17-20\u002F2018 and Marker Simulated Use Test Report TR-004 Rev L dated 02\u002F09\u002F2016 did not take the following critical user needs into account: variation in soft tissue types, anatomies of the patient population, the appropriate placement and fixation of the device into the patient, nor the appropriate depth of the implant into the soft tissue.\u003C\u002Fp>\u003Cp>d. You failed to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\u003Cbr>• The production of the devices was transferred to Costa Rica in November of 2022 after the quality system was updated to include BioZorb medical devices. Your Design History File does not include documentation that the device design was appropriately translated into production specifications and does not include identification of the product undergoing transfer and design review as required by Design Control SOP0018 dated 03\u002F01\u002F2011 and current Product Development Procedure ENG0100 dated 03\u002F19\u002F2024.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. We are aware that The BioZorb Product Line was put on Stop Ship Notice on September 29, 2024, and Hologic will not continue to manufacture the BioZorb product. We also understand that you will not be performing any specific design studies to address the above deficiencies. FDA continues to have safety concerns for patients in whom this device has been implanted. You have not appropriately evaluated your device design to ensure the following risks are mitigated for patients that already have the Biozorb device implanted, such as and not limited to: the potential of device interference with detection of cancer recurrence or new cancers; whether in-vivo radiation treatments can impact the performance of the device; and the ability of the device to resorb into the patient’s body. Your firm should address the contribution of the device design to adverse events and identify those patients who may be at risk for adverse events and therefore potentially benefit from intervention by device explantation.\u003C\u002Fp>\u003Cp>Additionally, you will be reviewing and revising design control procedures that focus on your remaining BSH products. However, your response does not yet include the documentation that includes your retrospective review of your BSH products and any remediation efforts that may be warranted after this review is completed.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology, as required by 21 CFR 820.100(a)(1). Specifically, your Corporate Corrective Action Preventive Action (CAPA) Procedure CORP-00007, Rev. 007 is not adequate. For example:\u003Cbr>• Your review of quality data was not sufficient to detect recurring problems. For example, in September of 2023, your firm received a spike of adverse event complaints regarding breast discomfort\u002Fpain, erythema, itching sensation, burning sensation, infection, scar tissue, sleep dysfunction, seroma, necrosis, additional surgery\u002Fdevice explantation, medication\u002Fscanning required, deformity\u002F disfigurement, migration, device palpability, and tissue damage\u002Fskin erosion. Your CAPA procedure only defines opening a CAPA if the severity of risk is considered high which the procedure defines as a severity level of 4 (critical) or 5 (catastrophic). Your firm’s management stated there is no justification for this rationale and a CAPA was not opened until May of 2024, to investigate the root cause of the adverse events that may not have risen to a severity level of 4 or 5.\u003Cbr>• You did not calculate the occurrence rate accurately when evaluating a spike of BioZorb medical device complaints and Medical Device Reports. Your Health Risk Assessment RSK-04622, dated March 8, 2024, does not take the patient population into account as required by Health Risk Assessment (HRA) procedure QUA-2364, dated August 14, 2020. This Assessment utilized units sold from 2016 to 2024 whereas the complaint data utilized in this review was from 2021 to 2024. Your procedure, QUA-3106, Investigation of Post Market Surveillance Spikes and Adverse Trends, step 7.2.3. discusses occurrence estimation and includes, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Neither the above referenced procedures, or your CAPA procedure, provide sufficient instructions for calculating an accurate occurrence rate when complaint spikes and adverse trends are identified, nor do they clearly define when a CAPA should be opened.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. We understand that you will be reviewing and revising your CAPA procedures moving forward. However, you have not described how you will be able to prevent this lack of oversight of your implementation of CAPA procedures in the future.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s BioZorb Marker is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that the firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fp>\u003Cp>The information provided in the Complaint Reports CPT-00635201, CPT-00661454, CPT-00624611, CPT-00732163, and CPT-00775690 reasonably suggests that patients developed infections following the implantation of your firm’s BioZorb Marker, needing antibiotic treatment and in some cases, surgical device explantation. We believe these medical or surgical interventions were needed to preclude permanent impairment of a body function or permanent damage to a body structure. Furthermore, there is no information in your firm’s complaint records that definitively rules out that the device may have been a factor in these serious injuries. As such, each of the referenced adverse events represents an MDR reportable serious injury event, as defined in 21 CFR 803.3. Your firm became aware of the events associated with CPT-00635201 on February 4, 2020, CPT-00661454 on April 14, 2020, CPT-00624611 on January 17, 2020, CPT-00732163 on September 16, 2020, and CPT-00775690 on December 7, 2020.\u003C\u002Fp>\u003Cp>However, your firm failed to submit an MDR for each referenced adverse event within the required 30-calendar-day timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response dated October 15, 2024, cannot be determined at this time.\u003C\u002Fp>\u003Cp>In the response, your firm states that it has initiated corrective actions to address the underlying root causes and plans to conduct a retrospective review of all BioZorb complaints for reportability. The response also noted your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm did not provide documentation or evidence of implementation of its systemic corrective actions as the planned corrective actions are still ongoing.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s BioZorb Sizer Set accessory devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: your firm conducted a correction of your BioZorb Sizer Set accessory device which can lead to probability of a serious adverse health consequence or death occurring as a result of using the device(s) under review is “reasonable”. You sent a customer notification letter to your customers instructing them to 1) immediately steam autoclave F0101 in accordance with the revised IFU sterilization parameters, and 2) when sterilizing the F0101, do not use the 2 layers or one layer of 2-ply wrap to provide a sterile barrier for each sterilization tray. The IFU supplied for these instructions for the sizers within F0101 has not yet been updated to reflect this change. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 11\u002F26\u002F2024, your firm submitted a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s response(s) to the FDA-483, dated 10\u002F15\u002F2024, is adequate. You submitted a Report of Correction or Removal to FDA as of 11\u002F26\u002F2024. However, your response does not contain evidence of completion of the updated procedures and documents. We recommend updating your procedures to follow the requirements under 21 CFR Part 806 Medical Devices; Reports of Corrections and Removals to ensure compliance; and recommend using the guidance provided by the 21 CFR Part 7 Recall Policy to ensure that all required information is provided or documented. In addition, we further recommend that you conduct health risk assessments following the definition of risk to health in 21 CFR 806.2(j), to support the reporting decisions for future medical device corrections or removals.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov to the attention of Gina Brackett, Assistant Director, Establishment Assessment Team 1. Refer to CMS case #698214 when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer, at (781-587-7491) or karen.archdeacon@fda.h\u003Ca>hs.gov.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Adam Gorzeman, Senior Director BSH Quality, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nStephen MacMillan\n\nRecipient Title\n\nCEO\u002FPresident\n\nHologic, Inc.\n\n250 Campus Drive\n\nMarlborough, MA 01752-3020\n\nUnited States\n\nSteve.MacMillan@hologic.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 698214\nDecember 18, 2024\nDear Mr. MacMillan:\nDuring an inspection of your firm located in Marlborough, MA on July 30, 2024, through September 24, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class II implantable radiographic markers, such as your BioZorb product line. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Adam Gorzeman, Senior Director BSH Quality, dated October 15, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We are aware that Hologic has made the decision to discontinue the manufacture of the BioZorb product line. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). You did not implement your Design Control Procedures, including Design Control SOP0018 dated 01\u002F31\u002F2017, Product Development Procedure ENG0100 dated 03\u002F19\u002F2024 and User Needs and Intended Use Statement Procedure ENG-0100-02 dated 04\u002F21\u002F2022. Specifically:\na. You failed to establish design inputs to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). The design history file for the BioZorb medical device product family:\n• Did not identify the intended patient population, nor did it address intended anatomy types, nor the surgical requirements such as the appropriate placement and fixation of the device, nor the appropriate depth of the implant into the soft tissue.\n• Did not include a requirement related to how in-vivo radiation treatments can impact the performance of the device and the ability of the device to resorb into the patient’s body.\n• Did not define the length of time for when the spacer material would be completely resorbed.\nb. You failed to verify your device design to confirm that the design output meets the design input requirements, as required by 21CFR 820.30(f).\n• Your firm does not have any verification testing to demonstrate that the bioabsorbable spacer material (poly lactic acid) is absorbed by the body. Your Design Description Document DDD-0001 dated August 22, 2017, includes a user requirement that the BioZorb medical device spacer material is resorbable into soft body tissue. Your verification testing report, VER-10394 dated June 27, 2022, only documents the inherent viscosity profile of the spacer during in-vitro degradation and does not provide sufficient data to support the claim that that spacer material is absorbed by the body. Your firm received complaints and filed Medical Device Reports regarding devices requiring explant and a lack of resorption, including Hologic Complaint Report CPT-01345922 which stated that the device failed to dissolve for almost five (5) years.\nc. You failed to validate your device design to ensure that devices conform to defined user\u002Fpatient needs and intended uses, as required by 21 CFR 820.30(g).\n• Your Design Validation studies performed under Marker Simulated Use Test Report TR-004 Rev P dated 08\u002F17-20\u002F2018 and Marker Simulated Use Test Report TR-004 Rev L dated 02\u002F09\u002F2016 did not take the following critical user needs into account: variation in soft tissue types, anatomies of the patient population, the appropriate placement and fixation of the device into the patient, nor the appropriate depth of the implant into the soft tissue.\nd. You failed to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\n• The production of the devices was transferred to Costa Rica in November of 2022 after the quality system was updated to include BioZorb medical devices. Your Design History File does not include documentation that the device design was appropriately translated into production specifications and does not include identification of the product undergoing transfer and design review as required by Design Control SOP0018 dated 03\u002F01\u002F2011 and current Product Development Procedure ENG0100 dated 03\u002F19\u002F2024.\nWe reviewed your firm’s response and concluded that it is not adequate. We are aware that The BioZorb Product Line was put on Stop Ship Notice on September 29, 2024, and Hologic will not continue to manufacture the BioZorb product. We also understand that you will not be performing any specific design studies to address the above deficiencies. FDA continues to have safety concerns for patients in whom this device has been implanted. You have not appropriately evaluated your device design to ensure the following risks are mitigated for patients that already have the Biozorb device implanted, such as and not limited to: the potential of device interference with detection of cancer recurrence or new cancers; whether in-vivo radiation treatments can impact the performance of the device; and the ability of the device to resorb into the patient’s body. Your firm should address the contribution of the device design to adverse events and identify those patients who may be at risk for adverse events and therefore potentially benefit from intervention by device explantation.\nAdditionally, you will be reviewing and revising design control procedures that focus on your remaining BSH products. However, your response does not yet include the documentation that includes your retrospective review of your BSH products and any remediation efforts that may be warranted after this review is completed.\n2. Failure to establish and maintain procedures for implementing corrective and preventive actions, including requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems using appropriate statistical methodology, as required by 21 CFR 820.100(a)(1). Specifically, your Corporate Corrective Action Preventive Action (CAPA) Procedure CORP-00007, Rev. 007 is not adequate. For example:\n• Your review of quality data was not sufficient to detect recurring problems. For example, in September of 2023, your firm received a spike of adverse event complaints regarding breast discomfort\u002Fpain, erythema, itching sensation, burning sensation, infection, scar tissue, sleep dysfunction, seroma, necrosis, additional surgery\u002Fdevice explantation, medication\u002Fscanning required, deformity\u002F disfigurement, migration, device palpability, and tissue damage\u002Fskin erosion. Your CAPA procedure only defines opening a CAPA if the severity of risk is considered high which the procedure defines as a severity level of 4 (critical) or 5 (catastrophic). Your firm’s management stated there is no justification for this rationale and a CAPA was not opened until May of 2024, to investigate the root cause of the adverse events that may not have risen to a severity level of 4 or 5.\n• You did not calculate the occurrence rate accurately when evaluating a spike of BioZorb medical device complaints and Medical Device Reports. Your Health Risk Assessment RSK-04622, dated March 8, 2024, does not take the patient population into account as required by Health Risk Assessment (HRA) procedure QUA-2364, dated August 14, 2020. This Assessment utilized units sold from 2016 to 2024 whereas the complaint data utilized in this review was from 2021 to 2024. Your procedure, QUA-3106, Investigation of Post Market Surveillance Spikes and Adverse Trends, step 7.2.3. discusses occurrence estimation and includes, “(b)(4).” Neither the above referenced procedures, or your CAPA procedure, provide sufficient instructions for calculating an accurate occurrence rate when complaint spikes and adverse trends are identified, nor do they clearly define when a CAPA should be opened.\nWe reviewed your firm’s response and concluded that it is not adequate. We understand that you will be reviewing and revising your CAPA procedures moving forward. However, you have not described how you will be able to prevent this lack of oversight of your implementation of CAPA procedures in the future.\nOur inspection also revealed that your firm’s BioZorb Marker is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that the firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that the firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\nThe information provided in the Complaint Reports CPT-00635201, CPT-00661454, CPT-00624611, CPT-00732163, and CPT-00775690 reasonably suggests that patients developed infections following the implantation of your firm’s BioZorb Marker, needing antibiotic treatment and in some cases, surgical device explantation. We believe these medical or surgical interventions were needed to preclude permanent impairment of a body function or permanent damage to a body structure. Furthermore, there is no information in your firm’s complaint records that definitively rules out that the device may have been a factor in these serious injuries. As such, each of the referenced adverse events represents an MDR reportable serious injury event, as defined in 21 CFR 803.3. Your firm became aware of the events associated with CPT-00635201 on February 4, 2020, CPT-00661454 on April 14, 2020, CPT-00624611 on January 17, 2020, CPT-00732163 on September 16, 2020, and CPT-00775690 on December 7, 2020.\nHowever, your firm failed to submit an MDR for each referenced adverse event within the required 30-calendar-day timeframe.\nThe adequacy of your firm’s response dated October 15, 2024, cannot be determined at this time.\nIn the response, your firm states that it has initiated corrective actions to address the underlying root causes and plans to conduct a retrospective review of all BioZorb complaints for reportability. The response also noted your firm (b)(4). However, your firm did not provide documentation or evidence of implementation of its systemic corrective actions as the planned corrective actions are still ongoing.\nOur inspection also revealed that your firm’s BioZorb Sizer Set accessory devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: your firm conducted a correction of your BioZorb Sizer Set accessory device which can lead to probability of a serious adverse health consequence or death occurring as a result of using the device(s) under review is “reasonable”. You sent a customer notification letter to your customers instructing them to 1) immediately steam autoclave F0101 in accordance with the revised IFU sterilization parameters, and 2) when sterilizing the F0101, do not use the 2 layers or one layer of 2-ply wrap to provide a sterile barrier for each sterilization tray. The IFU supplied for these instructions for the sizers within F0101 has not yet been updated to reflect this change. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of 11\u002F26\u002F2024, your firm submitted a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s response(s) to the FDA-483, dated 10\u002F15\u002F2024, is adequate. You submitted a Report of Correction or Removal to FDA as of 11\u002F26\u002F2024. However, your response does not contain evidence of completion of the updated procedures and documents. We recommend updating your procedures to follow the requirements under 21 CFR Part 806 Medical Devices; Reports of Corrections and Removals to ensure compliance; and recommend using the guidance provided by the 21 CFR Part 7 Recall Policy to ensure that all required information is provided or documented. In addition, we further recommend that you conduct health risk assessments following the definition of risk to health in 21 CFR 806.2(j), to support the reporting decisions for future medical device corrections or removals.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov to the attention of Gina Brackett, Assistant Director, Establishment Assessment Team 1. Refer to CMS case #698214 when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer, at (781-587-7491) or karen.archdeacon@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Adam Gorzeman, Senior Director BSH Quality, (b)(4)","Hologic, Inc.","hologic-inc-698214-12182024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhologic-inc-698214-12182024","2026-10-26T08:08:55.342437+00:00","Warning Letter","Issued","2025-01-14","698214","Medical Devices","Stephen MacMillan","2026-08-19T17:04:44.599+00:00","VIA Electronic Mail","2024-12-18",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},3130,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-09-28T13:20:00Z\">09\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-10T04:00:00Z\">09\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fholographic-health-inc-613874-09102021\">Holographic Health, Inc. \u003C\u002Fa>","Division of Human and Animal Food Operations East V","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Theodore Baroody\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Holographic Health, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>516 E. Market Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kingsport\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>37660\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 10, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Baroody:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the following Internet address: www.holographichealth.com. It was determined that you take orders for your products “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” “Pink Lady,” “Eye-C,” and Hemorr-Norm.” The claims on your website establish that these products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)(1)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>GLYCO-WELL\u003Cbr>\n• “GLYCO-WELL was formulated to regulate blood sugar issues”\u003Cbr>\n• “Regulates Blood Sugar”\u003Cbr>\n• “Gymnema Sylestre Extract [an ingredient listed in Glyco-Well] . . . Powerful herbal agent for effective blood sugar regulation”\u003Cbr>\n• “Jambolan [an ingredient listed in Glyco-Well] . . . An Ayurvedic botanical traditionally used to balance blood sugar levels”\u003C\u002Fp>\n\n\u003Cp>PAN-GEST\u003Cbr>\n• “Anything that has to do with the pancreas, health will be addressed with Pan-Gest including blood sugar regulation.”\u003Cbr>\n• “It is also helpful for regulating the inflammatory response.”\u003Cbr>\n• “Bromelain [an ingredient listed in Pan-Gest] . . . Very helpful for inflammation in the body around joints.”\u003Cbr>\n• “Celiac disease is a digestive disease that damages the small intestine and interferes with absorption of nutrients in food . . .”\u003C\u002Fp>\n\n\u003Cp>HEART-LINE\u003Cbr>\n• “Potassium Orotate [an ingredient listed in Heart-Line]. . . Used in heart rhythm regulation…”\u003Cbr>\n• “The dangers of hypertension are 1) heart attack and 2) stroke with paralysis. Heart-Line is formulated to help your system prevent this kind of problem from occurring.”\u003C\u002Fp>\n\n\u003Cp>ASPARA-CAN\u003Cbr>\n• “Mrs. M.C., nurse, had been diagnosed with a large breast tumor by her medical doctor. I gave her Aspara-Can capsules to help with her imbalanced heart beat [sic]. After two months, the heart normalized, and the breast tumor (which I do not treat) reduced by over 60%.!”\u003Cbr>\n• “[T]he healing power of asparagus in heart arrhythmia conditions. . .”\u003C\u002Fp>\n\n\u003Cp>CHERRY GOLD\u003Cbr>\n• “Arthritis and all of its related “itis” conditions plague millions worldwide. With all the new information about the anti-arthritis drugs being dangerous, you may find Cherry Gold of great value . . . taking Cherry Gold if the joint pain is moderate to severe.”\u003Cbr>\n• “Black Cherry Powder [an ingredient listed in Cherry Gold]. . . maintaining healthy uric acid levels. When uric acid levels are not kept in the normal range, the body is more prone to gout and joint inflammation. Cherries have a long history of supporting optimal inflammatory response.”\u003Cbr>\n• “Bromelain [an ingredient listed in Cherry Gold] . . . Helpful for pain . . .”\u003Cbr>\n• “Goat’s Rue [an ingredient listed in Cherry Gold] . . . recommended . . . for pain relief”\u003Cbr>\n• “Nutmeg [an ingredient listed in Cherry Gold] . . . for pain relief”\u003C\u002Fp>\n\n\u003Cp>H.H.S FORMULA\u003Cbr>\n• “Marshmallow root [an ingredient listed in H.H.S. Formula] . . . Marshmallow is most commonly used to treat sore throats and dry coughs. The Marshmallow plant, especially the leaves and roots, contains polysaccharides that have antitussive … and antibacterial properties.”\u003Cbr>\n• “Ginger root [an ingredient listed in H.H.S. Formula] . . . Enough scientific research exists to support ginger’s ability to help reduce nausea from chemotherapy treatments . . . It seems particularly good for hiatal hernia sufferers.”\u003Cbr>\n• “Slippery elm bark [an ingredient listed in H.H.S. Formula] . . . contains a substance called mucilage . . . causing much relief from things like Gastroesophageal Reflux Disease (GERT) . . . Crohn’s Disease, ulcerative colitis, diarrhea, diverticulitis and Irritable Bowel Syndrome [sic] (IBS).”\u003Cbr>\n• “Fennel [an ingredient listed in H.H.S. Formula] . . . It is a tested remedy for . . . acid stomach, gout, cramps, colic and spasms . . . Excellent for obesity.”\u003C\u002Fp>\n\n\u003Cp>BRAIN BALANCE (Formerly TRI-FORCE)\u003Cbr>\n• \"Tri-Force supports the endocrine system nutritionally. Researched and documented issues of the pituitary are: . . . excessive urination . . . chronic headaches . . .non-insulin responsive diabetic. . . sexual problems . . . mental illness . . .numbness and tingling sensations”\u003C\u002Fp>\n\n\u003Cp>PASSIONATE PURSUIT\u003Cbr>\n• “[I]t is focused on increasing testosterone secretions from the glands related to this function. This . . . should assist in erectile dysfunction problems.”\u003Cbr>\n• “The ‘price is right’ for Passionate Pursuit. Cialis is selling for $16 dollars a pill at the drug store and [sic] other natural enhancers are three times as much as we are charging!”\u003Cbr>\n• “Tribulus Terrestris Fruit [an ingredient listed in Passionate Pursuit]: This ingredient helps with . . . impotence, inability to maintain an erection . . .”\u003Cbr>\n• “Korean Ginseng Root [an ingredient listed in Passionate Pursuit] . . . Modern therapeutic uses refers to . . . cardiovascular diseases . . .”\u003Cbr>\n• “Potency Wood Bark [an ingredient listed in Passionate Pursuit]: . . . helps with . . . impotence. It has been used successfully in studies to treat erectile dysfunction”\u003Cbr>\n• “Gingko Biloba Leaf [an ingredient listed in Passionate Pursuit]: . . . may help support . . . impotence . . . In one study 78% of a group of men with impotence reported significant improvements without side effects.”\u003Cbr>\n• “Cnidium Monnieri Seed Extract [an ingredient listed in Passionate Pursuit] . . . it has been used to treat male sexual dysfunction.”\u003Cbr>\n• “The Velvet Bean[an ingredient listed in Passionate Pursuit] has many traditional and medicinal usages including treating pain, cholera, diabetes, infertility, scorpion bites, snakebites, toothaches . . . reduces inflammation . . . kills some parasites . . . reduces spasms…lowers blood sugars, reduces fever, lowers cholesterol. . .”\u003Cbr>\n• “Damiana Leaf [an ingredient listed in Passionate Pursuit]: . . . known for its help with impotence . . .”\u003C\u002Fp>\n\n\u003Cp>BETTER MOOD\u003Cbr>\n• “depression . . . Imbalances are . . . anxieties, phobias . . . manic-depression (bipolar) . . . One in a hundred people is diagnosed as suffering from schizophrenia. Better Mood is aimed at balancing the brain nutritionally and to stabilize it by a totally natural method.”\u003Cbr>\n• “Lithium Orotate [an ingredient listed in Better Mood] . . . balance a depressive state.”\u003Cbr>\n• “Dimethylaminoethanol (DMAE) [an ingredient listed in Better Mood] . . . It is excellent for depression, anxiety, and hyperactivity.”\u003C\u002Fp>\n\n\u003Cp>MALE PROSEXUAL\u003Cbr>\n• “It is focused on increasing testosterone secretions from the glands related to this function. This . . . should assist in erectile dysfunction problems.”\u003Cbr>\n• “The ‘price is right’ for Male Prosexual. Cialis is selling for $41 dollars a pill at the drug store, and other natural enhancers are twice as much as we are charging!”\u003C\u002Fp>\n\n\u003Cp>EAR WELL\u003Cbr>\n• “All Natural Oil Formulation For Ear Imbalances”\u003Cbr>\n• “Otitis media is the number one problem for children today…Most ear infections are the result of fungus.”\u003C\u002Fp>\n\n\u003Cp>PINK LADY\u003Cbr>\n• “A Transdermal Vitamin B12 Cream”\u003Cbr>\n• “Very mild to very severe B12 deficiencies can cause different levels of problems. The list of imbalances that nutritional research has revealed related to B12 insufficiencies are startling. These are: . . . Depression . . . Shooting Pains . . . Menstrual Disturbances . . . Celiac Disease.”\u003Cbr>\n• “As usual, we are making no claims that this product will work, but my clientele love it. It sure beats taking injections, if you can get them at all.”\u003Cbr>\n• “There is some research that B12 is linked to autoimmune imbalances. This is where the immune system goes haywire and produces antibodies that fight against the body’s own tissues. In conclusion, we all need B12. Practically everyone will benefit by getting more that they are presently absorbing in their systems.”\u003C\u002Fp>\n\n\u003Cp>EYE-C\u003Cbr>\n• An image of the product with the container label bearing the text “A NATURAL EYE SUPPORT” on the label\u003Cbr>\n• “A Natural Eye Wash For All Complaints”\u003Cbr>\n• “‘The Windows of the Soul’ need [to be] . . . nourished and protected. When I formulated EYE-C, all these considerations were made. Particularly, I was attempting to ‘feed the eye.’”\u003Cbr>\n• “Use one drop in each eye one to three times a day depending upon your situation. It stings a little when you first put it in, but stops very soon. This is because you really need it. The more the sting, the more the need. Sometimes one eye will sting more than the other which means that particular eye is stressed more than the other.”\u003C\u002Fp>\n\n\u003Cp>HEMORR-NORM\u003Cbr>\n• An image of the product with the container label bearing the text “A SOOTHING OINTMENT FOR HEMORRHOID, BURN, AND INSECT BITE IMBALANCES” on the label\u003Cbr>\n• “There are different types of hemorrhoids. Some bleed, some protrude, some hurt, and some don’t. But all are problematical [sic]. It appears that what causes their presence is a rather complicated mater. It is not just excessive lifting or constipation. It is involved with many interrelated body systems. Among these are coccyx problems and bowel imbalances. I have also recommended this ointment for excessively rough cracking skin on the feet and hands with excellent results. It can also be used on eternal sores.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Information on your website at www.holographichealth.com indicates that you intend to market your “Pink Lady” product as a dietary supplement. For example, “Pink Lady” is labeled with a Supplement Facts panel; however, it is marketed for topical use. “Pink Lady” does not meet the definition of a dietary supplement under section 201(ff)(2)(A)(i) of the FD&amp;C Act, [21 U.S.C. 321(ff)(2)(A)(i)]. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. Topical products and products intended to enter the body through the skin or mucosal tissues are not intended for ingestion. Therefore, your “Pink Lady” is not a dietary supplement under section 201(ff) of the FD&amp;C Act, [21 U.S.C. § 321(ff)].\u003C\u002Fp>\n\n\u003Cp>Your “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” “Pink Lady,” “Eye-C,” and “Hemorr-Norm” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No approved applications are in effect for your products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” and “Pink Lady,” products are misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)], in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to U.S. Food and Drug Administration, Attention: Allison C. Hunter, Compliance Officer, 6751 Steger Drive, Cincinnati, Ohio 45237. If you have any questions with regard to this letter, please contact Allison C. Hunter, at (513) 679-2700 Ext. 2134 or via email at ORAHAFEAST5FirmResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTheodore Baroody\n\nRecipient Title\n\nPresident\n\nHolographic Health, Inc.\n\n516 E. Market Street\n\nKingsport, TN 37660\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nWARNING LETTER\n\nSeptember 10, 2021\n\nDear Mr. Baroody:\n\nThis letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the following Internet address: www.holographichealth.com. It was determined that you take orders for your products “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” “Pink Lady,” “Eye-C,” and Hemorr-Norm.” The claims on your website establish that these products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)(1)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or function of the body. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nGLYCO-WELL\n\n• “GLYCO-WELL was formulated to regulate blood sugar issues”\n\n• “Regulates Blood Sugar”\n\n• “Gymnema Sylestre Extract [an ingredient listed in Glyco-Well] . . . Powerful herbal agent for effective blood sugar regulation”\n\n• “Jambolan [an ingredient listed in Glyco-Well] . . . An Ayurvedic botanical traditionally used to balance blood sugar levels”\n\nPAN-GEST\n\n• “Anything that has to do with the pancreas, health will be addressed with Pan-Gest including blood sugar regulation.”\n\n• “It is also helpful for regulating the inflammatory response.”\n\n• “Bromelain [an ingredient listed in Pan-Gest] . . . Very helpful for inflammation in the body around joints.”\n\n• “Celiac disease is a digestive disease that damages the small intestine and interferes with absorption of nutrients in food . . .”\n\nHEART-LINE\n\n• “Potassium Orotate [an ingredient listed in Heart-Line]. . . Used in heart rhythm regulation…”\n\n• “The dangers of hypertension are 1) heart attack and 2) stroke with paralysis. Heart-Line is formulated to help your system prevent this kind of problem from occurring.”\n\nASPARA-CAN\n\n• “Mrs. M.C., nurse, had been diagnosed with a large breast tumor by her medical doctor. I gave her Aspara-Can capsules to help with her imbalanced heart beat [sic]. After two months, the heart normalized, and the breast tumor (which I do not treat) reduced by over 60%.!”\n\n• “[T]he healing power of asparagus in heart arrhythmia conditions. . .”\n\nCHERRY GOLD\n\n• “Arthritis and all of its related “itis” conditions plague millions worldwide. With all the new information about the anti-arthritis drugs being dangerous, you may find Cherry Gold of great value . . . taking Cherry Gold if the joint pain is moderate to severe.”\n\n• “Black Cherry Powder [an ingredient listed in Cherry Gold]. . . maintaining healthy uric acid levels. When uric acid levels are not kept in the normal range, the body is more prone to gout and joint inflammation. Cherries have a long history of supporting optimal inflammatory response.”\n\n• “Bromelain [an ingredient listed in Cherry Gold] . . . Helpful for pain . . .”\n\n• “Goat’s Rue [an ingredient listed in Cherry Gold] . . . recommended . . . for pain relief”\n\n• “Nutmeg [an ingredient listed in Cherry Gold] . . . for pain relief”\n\nH.H.S FORMULA\n\n• “Marshmallow root [an ingredient listed in H.H.S. Formula] . . . Marshmallow is most commonly used to treat sore throats and dry coughs. The Marshmallow plant, especially the leaves and roots, contains polysaccharides that have antitussive … and antibacterial properties.”\n\n• “Ginger root [an ingredient listed in H.H.S. Formula] . . . Enough scientific research exists to support ginger’s ability to help reduce nausea from chemotherapy treatments . . . It seems particularly good for hiatal hernia sufferers.”\n\n• “Slippery elm bark [an ingredient listed in H.H.S. Formula] . . . contains a substance called mucilage . . . causing much relief from things like Gastroesophageal Reflux Disease (GERT) . . . Crohn’s Disease, ulcerative colitis, diarrhea, diverticulitis and Irritable Bowel Syndrome [sic] (IBS).”\n\n• “Fennel [an ingredient listed in H.H.S. Formula] . . . It is a tested remedy for . . . acid stomach, gout, cramps, colic and spasms . . . Excellent for obesity.”\n\nBRAIN BALANCE (Formerly TRI-FORCE)\n\n• \"Tri-Force supports the endocrine system nutritionally. Researched and documented issues of the pituitary are: . . . excessive urination . . . chronic headaches . . .non-insulin responsive diabetic. . . sexual problems . . . mental illness . . .numbness and tingling sensations”\n\nPASSIONATE PURSUIT\n\n• “[I]t is focused on increasing testosterone secretions from the glands related to this function. This . . . should assist in erectile dysfunction problems.”\n\n• “The ‘price is right’ for Passionate Pursuit. Cialis is selling for $16 dollars a pill at the drug store and [sic] other natural enhancers are three times as much as we are charging!”\n\n• “Tribulus Terrestris Fruit [an ingredient listed in Passionate Pursuit]: This ingredient helps with . . . impotence, inability to maintain an erection . . .”\n\n• “Korean Ginseng Root [an ingredient listed in Passionate Pursuit] . . . Modern therapeutic uses refers to . . . cardiovascular diseases . . .”\n\n• “Potency Wood Bark [an ingredient listed in Passionate Pursuit]: . . . helps with . . . impotence. It has been used successfully in studies to treat erectile dysfunction”\n\n• “Gingko Biloba Leaf [an ingredient listed in Passionate Pursuit]: . . . may help support . . . impotence . . . In one study 78% of a group of men with impotence reported significant improvements without side effects.”\n\n• “Cnidium Monnieri Seed Extract [an ingredient listed in Passionate Pursuit] . . . it has been used to treat male sexual dysfunction.”\n\n• “The Velvet Bean[an ingredient listed in Passionate Pursuit] has many traditional and medicinal usages including treating pain, cholera, diabetes, infertility, scorpion bites, snakebites, toothaches . . . reduces inflammation . . . kills some parasites . . . reduces spasms…lowers blood sugars, reduces fever, lowers cholesterol. . .”\n\n• “Damiana Leaf [an ingredient listed in Passionate Pursuit]: . . . known for its help with impotence . . .”\n\nBETTER MOOD\n\n• “depression . . . Imbalances are . . . anxieties, phobias . . . manic-depression (bipolar) . . . One in a hundred people is diagnosed as suffering from schizophrenia. Better Mood is aimed at balancing the brain nutritionally and to stabilize it by a totally natural method.”\n\n• “Lithium Orotate [an ingredient listed in Better Mood] . . . balance a depressive state.”\n\n• “Dimethylaminoethanol (DMAE) [an ingredient listed in Better Mood] . . . It is excellent for depression, anxiety, and hyperactivity.”\n\nMALE PROSEXUAL\n\n• “It is focused on increasing testosterone secretions from the glands related to this function. This . . . should assist in erectile dysfunction problems.”\n\n• “The ‘price is right’ for Male Prosexual. Cialis is selling for $41 dollars a pill at the drug store, and other natural enhancers are twice as much as we are charging!”\n\nEAR WELL\n\n• “All Natural Oil Formulation For Ear Imbalances”\n\n• “Otitis media is the number one problem for children today…Most ear infections are the result of fungus.”\n\nPINK LADY\n\n• “A Transdermal Vitamin B12 Cream”\n\n• “Very mild to very severe B12 deficiencies can cause different levels of problems. The list of imbalances that nutritional research has revealed related to B12 insufficiencies are startling. These are: . . . Depression . . . Shooting Pains . . . Menstrual Disturbances . . . Celiac Disease.”\n\n• “As usual, we are making no claims that this product will work, but my clientele love it. It sure beats taking injections, if you can get them at all.”\n\n• “There is some research that B12 is linked to autoimmune imbalances. This is where the immune system goes haywire and produces antibodies that fight against the body’s own tissues. In conclusion, we all need B12. Practically everyone will benefit by getting more that they are presently absorbing in their systems.”\n\nEYE-C\n\n• An image of the product with the container label bearing the text “A NATURAL EYE SUPPORT” on the label\n\n• “A Natural Eye Wash For All Complaints”\n\n• “‘The Windows of the Soul’ need [to be] . . . nourished and protected. When I formulated EYE-C, all these considerations were made. Particularly, I was attempting to ‘feed the eye.’”\n\n• “Use one drop in each eye one to three times a day depending upon your situation. It stings a little when you first put it in, but stops very soon. This is because you really need it. The more the sting, the more the need. Sometimes one eye will sting more than the other which means that particular eye is stressed more than the other.”\n\nHEMORR-NORM\n\n• An image of the product with the container label bearing the text “A SOOTHING OINTMENT FOR HEMORRHOID, BURN, AND INSECT BITE IMBALANCES” on the label\n\n• “There are different types of hemorrhoids. Some bleed, some protrude, some hurt, and some don’t. But all are problematical [sic]. It appears that what causes their presence is a rather complicated mater. It is not just excessive lifting or constipation. It is involved with many interrelated body systems. Among these are coccyx problems and bowel imbalances. I have also recommended this ointment for excessively rough cracking skin on the feet and hands with excellent results. It can also be used on eternal sores.\n\nUnapproved New Drugs\n\nInformation on your website at www.holographichealth.com indicates that you intend to market your “Pink Lady” product as a dietary supplement. For example, “Pink Lady” is labeled with a Supplement Facts panel; however, it is marketed for topical use. “Pink Lady” does not meet the definition of a dietary supplement under section 201(ff)(2)(A)(i) of the FD&C Act, [21 U.S.C. 321(ff)(2)(A)(i)]. Only products that are intended solely for ingestion may be lawfully marketed as dietary supplements. Topical products and products intended to enter the body through the skin or mucosal tissues are not intended for ingestion. Therefore, your “Pink Lady” is not a dietary supplement under section 201(ff) of the FD&C Act, [21 U.S.C. § 321(ff)].\n\nYour “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” “Pink Lady,” “Eye-C,” and “Hemorr-Norm” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. No approved applications are in effect for your products.\n\nMisbranded Drugs\n\nYour “Glyco-Well,” “Pan-Gest,” “Heart-Line,” “Aspara-Can,” “Cherry Gold,” “H.H.S. Formula,” “Brain Balance,” “Passionate Pursuit,” “Better Mood,” “Male Prosexual,” “Ear Well,” and “Pink Lady,” products are misbranded within the meaning of section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)], in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, 21 CFR 201.100(c)(2) and 201.115, because no FDA-approved applications are in effect for them. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to U.S. Food and Drug Administration, Attention: Allison C. Hunter, Compliance Officer, 6751 Steger Drive, Cincinnati, Ohio 45237. If you have any questions with regard to this letter, please contact Allison C. Hunter, at (513) 679-2700 Ext. 2134 or via email at ORAHAFEAST5FirmResponses@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Holographic Health, Inc.","holographic-health-inc-613874-09102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fholographic-health-inc-613874-09102021","2026-10-26T08:08:55.384977+00:00","2021-09-28","613874","DrugsFood & Beverages","Theodore Baroody","2026-08-20T02:35:27.29+00:00","Via Overnight Delivery","2021-09-10",{"id":54,"raw":55,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":75,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},899,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-16T05:00:00Z\">12\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024\">Skye Biologics Holdings LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)\u003Cbr \u002F>\r\n","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-654466\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher M.B. Sharp\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skye Biologics Holdings LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2255 Campus Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Segundo\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90245-0001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CBER-24-654466&nbsp;\u003C\u002Fp>\u003Cp>December 16, 2024&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Sharp:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>”).&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\u003C\u002Fli>\u003Cli>In a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s &amp; Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR parts 210 and 211.\u003C\u002Fp>\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\u003C\u002Fp>\u003Cp>The CGMP violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a).\u003C\u002Fstrong> Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b).\u003C\u002Fstrong> Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\u003C\u002Fp>\u003Cp>a. You do not perform nonviable particulate monitoring or viable microbial \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\u003C\u002Fp>\u003Cp>b. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b).\u003C\u002Fstrong> For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, &nbsp;quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b).\u003C\u002Fstrong> Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. \u003C\u002Fstrong>For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b).\u003C\u002Fstrong> Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\u003C\u002Fp>\u003Cp>a. The weight of, for e.g., umbilical cord tissue used in processing.\u003C\u002Fp>\u003Cp>b. The amount of saline used to formulate the final product.\u003C\u002Fp>\u003Cp>c. Processing of tissue in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\u003C\u002Fp>\u003Cp>d. Identification of equipment, such as laminar flow hoods, used in processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a).\u003C\u002Fstrong> Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\u003C\u002Fp>\u003Cp>Your firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\u003C\u002Fp>\u003Cp>As such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.&nbsp;\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.&nbsp;\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER-24-654466\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nChristopher M.B. Sharp\n\nRecipient Title\n\nChief Executive Officer\n\nSkye Biologics Holdings LLC\n\n2255 Campus Dr\n\nEl Segundo, CA 90245-0001\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nCBER-24-654466\nDecember 16, 2024\nDear Mr. Sharp:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at 2255 Campus Dr, El Segundo, CA 90245, between November 29, 2022 and December 9, 2022. During the inspection, FDA documented that your company manufactures “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioECM™ (collectively, “your products1”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your introduction or delivery for introduction of your product[s] into interstatecommerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act,21 U.S.C. § 331(d). Your products are also unlicensed biological products in violation of section 351(a) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your adulterated products into interstate commerce is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA prior to, during, and\u002For after the inspection, including information on your website, www.skyebiologics.com, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour webpage for “Tissue Transplants Utilizing Extracellular Matrix Preservation (BioECM) Technology”, located at https:\u002F\u002Fwww.skyebiologics.com\u002Ftechnology, states that “Not all Placental Allografts are Created Equal… Placental tissues have been shown in the literature to be naturally anti-inflammatory, anti-fibrotic, anti-microbial, to modulate inflammation, promote tissue remodeling and reduce scar tissue formation in clinical applications.”\nIn a press release regarding your BioECM product, you state that “FastActing Amniotic Membranes are part of HRT’s & Skye’s extensive line of amniotic and placental products designed to help support proper tissue remodeling while modulating scarring and inflammation.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including, as applicable, premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form, drastically alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended solely to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, your products are intended for, e.g., modulation of inflammation and promotion of remodeling of tissues; anti-inflammatory, anti-fibrotic, and anti-microbial purposes; and supplementing or filling a void, which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, these products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nAdditionally, during the inspection, FDA investigators documented evidence of significant violations from CGMP requirements, including violations from section 501(a)(2)(B) of the FD&C Act and 21 CFR parts 210 and 211.\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant violations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during the November 2022 inspection, as discussed below.\nThe CGMP violations include, but are not limited to, the following:\n1. Failure to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. 21 CFR 211.100(a). Specifically, your firm has not validated the manufacturing processes for your products with respect to identity, strength, quality, and purity.\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area, 21 CFR 211.42(c)(10)(iv), as well as failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile. 21 CFR 211.113(b). Your written procedures for environmental monitoring of your firm’s aseptic processing areas (e.g., laminar flow hoods) are not sufficient to detect problems and ensure low bioburden levels prior to sterilization. For example,\na. You do not perform nonviable particulate monitoring or viable microbial (b)(4) monitoring within your ISO 5 laminar flow hoods in association with all production shifts. You also do not conduct personnel monitoring of operators who perform processing of your products. Due to the higher risk of microbial contamination in this environment where open processing occurs, environmental monitoring inside the laminar flow hood should be conducted in association with each batch.\nb. Your ISO 5 laminar flow hoods, which are used for tissue cleaning, rinsing, and weighing, are located within an unclassified area. The area immediately adjacent to the critical processing areas should be controlled and monitored to minimize the level of potential contaminants in the final product.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure the components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality and purity. 21 CFR211.160(b). For example, you have not established appropriate specifications to assure that your products conform to appropriate standards of identity, strength, quality, and purity.\n4. Failure to perform appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.21 CFR 211.165(b). Specifically, you failed to perform endotoxin testing on final product batches. Such laboratory testing is necessary as your products are purported to be sterile.\n5. Failure to thoroughly investigate any unexplained discrepancy or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. 21 CFR 211.192. For example, from January 2021 to August 2022, you failed to investigate three action-level excursions for environmental monitoring observed in the a septic processing area (e.g., laminar flow hoods).\n6. Failure to prepare batch production and control records that document each significant step in the manufacture, processing, packing, or holding of your umbilical cord blood products. 21 CFR 211.188(b). Specifically, your batch production records do not include documentation of the accomplishment of each significant step in the manufacture of your products or the person(s) performing each of those steps, for example:\na. The weight of, for e.g., umbilical cord tissue used in processing.\nb. The amount of saline used to formulate the final product.\nc. Processing of tissue in the (b)(4) machine, including weight of tissue processed, machine operational parameters, run time, and the number of runs completed.\nd. Identification of equipment, such as laminar flow hoods, used in processing.\n7. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates. 21 CFR 211.166(a). Specifically, your firm has assigned a five-year expiration date for your products without supporting data regarding the stability characteristics of the products.\nResponse to the Form FDA-483\nWe acknowledge receipt of your letter received on January 3, 2023, which provides a response to FDA’s inspectional observations (FDA-483). We have reviewed the represented corrective actions outlined in the response, and these actions are not adequate to address the above-noted violations. For example, your response does not address your firm’s continued manufacture and distribution of your products or your plans for disposition of your current inventory manufactured under the violative conditions outlined above.\nYour firm’s response repeatedly asserts that your products should be regulated solely under section 361 of the PHS Act, and that the violations noted above are not applicable to your products. Based on your position, you have not proposed corrective actions which address the CGMP violations noted above. While you assert that your products should be regulated solely under section 361 of the PHS Act, as explained above, the available evidence shows that your products do not meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271.\nAs such, your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent.\nAdditional Concerns\nIn addition, we have concerns with your “placental connective tissue matrix allograft” products derived from umbilical cord, namely BioRenew™, and products derived from amniotic and chorionic membrane and umbilical cord, namely HRT® BioPower-A, HRT® BioPower-C, and HRT® NX. In your response, please explain the basis for your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet all criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure that your establishment is in full compliance with the law.\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions may include seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent any violations, or similar violations, from occurring again. Include any documentation necessary to show that these matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 You market your BioECM™ products as BioECM ActiveMatrix®, BioECM BurnMatrix®, BioECM CryoMatrix®, BioECM MX™, BioECM NX™, BioECM RX, BioECM WoundEx™.\n2 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all of the other criteria in 21 CFR 1271.10(a).","Skye Biologics Holdings LLC","skye-biologics-holdings-llc-654466-12162024","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskye-biologics-holdings-llc-654466-12162024","2026-10-26T08:09:58.907333+00:00","2025-05-20","654466","Biologics","Christopher M.B. Sharp","2026-08-19T16:46:38.883+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","CBER-24-654466","2024-12-16",{"id":78,"raw":79,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":18,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":95,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},1078,[80,81,82,59,83,13,13,13],"\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-17T05:00:00Z\">01\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchara-biologics-inc-698004-01172025\">Chara Biologics, Inc.\u003C\u002Fa>","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-25-698004\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joy Kong, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chara Biologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9568 Topanga Canyon Blvd., Suite 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chatsworth\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91311\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>January 17, 2025\u003C\u002Fp>\u003Cp>CBER 25-698004\u003C\u002Fp>\u003Cp>Dear Dr. Kong:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, Chara Biologics, Inc., located at the above address, between July 23, 2024, and August 16, 2024. During the inspection, FDA documented that Chara Biologics, Inc. (“you”) manufactures and distributes a human amniotic fluid product, CharaExo, as well as cellular products derived from human umbilical cord, CharaCore and CharaOmni, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Your firm is responsible for ensuring that your products comply with CGMP requirements regardless of who manufactures, processes, packs, or holds them. This letter also explains you are in violation of current good tissue practice (CGTP) requirements set forth in 21 CFR part 1271 in the manufacture of your CharaCore and CharaOmni products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Furthermore, CharaExo is also misbranded under sections 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans. For example:\u003C\u002Fp>\u003Cp>• CharaExo\u003Cbr>&nbsp; o Chara Biologics’ brochure, “Let the Joy of Healing Begin,” tells prospective customers to choose its products because “Chara offers the most comprehensive stem cell product CharaCore and high potency growth factor\u002Fextracellular vesicle product CharaExo.” It explains that “stem cells have been shown to have clinical benefits in” a long list of conditions including various autoimmune disorders, “neurodegenerative conditions (Parkinson’s, Alzheimers, Multiple Sclerosis, ALS, etc.)”, diabetes, cardiovascular and lung diseases, autism, spinal cord injuries, and cirrhosis. It also explains stem cell treatment can benefit its audience by reducing inflammation, improving immune function, and enhancing tissue repair.\u003Cbr>&nbsp; o AAICT “Exosome Protocols” provide sample CharaExo dosing for the following diseases or conditions: Infertility, Osteoporosis, Diabetes, Autism, Cardiac, Renal, Hepatic, Pulmonary conditions, etc…. Musculoskeletal…Shoulder\u002FHip\u002FKnees…Ligaments\u002FTendons\u002FMeniscus \u002FLabrum… Elbow\u002FWrist\u002FAnkle\u002FFingers… Spine…Erectile Dysfunction… Female Urinary Incontinence…Autoimmune Diseases… Neuropathy… CNS Disease… Wound, Ulcers &amp; Burns…” These protocols, which are part of AAICT’s Fundamentals of Stem Cell Practice course, accompany Chara Biologics’ CharaExo products when Chara Biologics sells them to physicians as part of Starter Package 3.\u003Cbr>&nbsp; o Chara Biologics’ “FAQs for Physicians,” which you said you provide all your purchasing physicians, explains: “CharaExo also contains larger extracellular vesicles, as well as concentrated growth factors from amniotic fluid… Extracellular vesicles contain proteins, microRNAs and lipids, and all eukaryotic cells secrete and take up these nanoparticles, and they are a means of communication between cells. These nanoparticles have been increasingly recognized as playing an important role as the mediator of many of the MSC-associated therapeutic benefits. They can be quite useful therapeutically, as they may elicit a more immediate therapeutic response, although the benefits tend to be shorter-lasting than that of cell therapy.”\u003C\u002Fp>\u003Cp>• CharaCore\u003Cbr>&nbsp; o Statements in Chara Biologics’ “Let the Joy of Healing Begin” brochure (discussed above)\u003Cbr>&nbsp; o Chara Biologics’ FAQ for Physicians includes the following statements:\u003Cbr>&nbsp; &nbsp;  “CharaCore® is highly rich in MSC’s…MSC’s: have anti-microbial properties, helpful in fighting acute, chronic or systemic infections… shown to be effective against protozoa (as in Lyme disease)”\u003Cbr>&nbsp; &nbsp;  “How Can CharaCore help my patients? REGULATE INFLAMMATION, SCARRING &amp; PAIN Birth tissue products have been shown to reduce inflammation, fibrous tissue growth, and potential scar tissue formation.”\u003Cbr>&nbsp; &nbsp;  “How Can CharaCore help my patients? ANTI-MICROBIAL Application of birth tissue products has been shown to reduce bacteria counts in the wound…”\u003C\u002Fp>\u003Cp>• CharaOmni\u003Cbr>&nbsp; o Chara Biologics’ FAQ for Physicians and CharaOmni promotional brochure state: “[W]hat set[s] CharaOmni apart from all other skincare products on the market: 1) Regenerative Stem Cell Components… Wharton’s Jelly Extract… reduces scar formation, and enhances wound healing…. Amniotic Extracellular Matrix - possesses powerful anti-inflammatory...properties.”\u003Cbr>&nbsp; o Your website at www.charaomni.com explains “The stem cell regenerative elements in CharaOmni… have been known to provide crucial and powerful growth factors, extracellular matrix, as well as other cell signaling molecules that highly beneficial in skin repair and regeneration.”\u003C\u002Fp>\u003Cp>• Chara Biologics also promotes its products for the following diseases at www.charabiologics.com\u002Fscience, which links to https:\u002F\u002Faaict.org\u002Fclinical-evidence\u002F:\u003Cbr>&nbsp; o “…Alzheimer’s…Asthma…Autism…Chronic Pain…COPD…Crohn’s Disease…Degenerative Disc Disease…Heart Disease…Kidney Failure…Liver Cirrhosis…Lupus…Macular Degeneration…Migraines &amp; Tension Headache…Multiple Sclerosis…Nerve Injury…Osteoarthritis… Osteoporosis…Parkinson’s…”\u003C\u002Fp>\u003Cp>Therefore, CharaExo, CharaCore, and CharaOmni are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your CharaCore and CharaOmni products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Chara Biologics, Inc. does not qualify for any exception in 21 CFR 1271.15, and your CharaCore and CharaOmni products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your CharaCore and CharaOmni products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your CharaCore and CharaOmni products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). These products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, these products are intended for use in the treatment of a number of diseases and conditions listed above, which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your CharaCore and CharaOmni products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA, nor is there an investigational new drug application (IND) in effect for any of them.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP and\u002For CGTP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP and CGTP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish a quality unit with the responsibility and authority to approve or reject all labeling and drug products, and the responsibilities and procedures applicable to the quality control unit are not in writing and followed, as required by 21 CFR 211.22(a) and 211.22(d).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a manufacturer subject to CGMP requirements. See 21 CFR 210.3(b)(12). For example, at the time of the inspection, your firm relabeled, stored, and distributed CharaCore and stored and distributed CharaOmni.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An adequate quality unit overseeing all elements of CGMP is necessary to ensure drug products are consistently manufactured in compliance with CGMP and meet established specifications for identity, strength, quality and purity. However, your firm does not receive documentation, such as production records or test results, for each lot received for approval or rejection by your firm before distribution. Additionally, your firm has not established responsibilities and procedures applicable to the quality unit such as the following:\u003C\u002Fp>\u003Cp>a. Laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b))\u003Cbr>b. Written procedures for production and process control designed to assure drug products have the identity, strength, quality, and purity purported or represented to possess (21 CFR 211.100(a))\u003Cbr>c. Review and approval of drug product production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192)\u003Cbr>d. Written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a))\u003Cbr>e. Written procedures designed to assure that correct labels, labeling, and packaging are used (21 CFR 211.130)\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Documentation of the donor-eligibility determination, including the name of the responsible person who made the determination and the date of the determination, was not maintained, as required by 21 CFR 1271.55(d)(1)(iii).\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>Specifically, Chara did not maintain documentation of the donor eligibility determination, including the name of the responsible person who made the determination and the date of the determination, for donors of umbilical cord. Umbilical cord is used to manufacture CharaCore, which is used to manufacture CharaOmni.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranding Violation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your CharaExo product is also misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a), because your labeling is false or misleading. Specifically, your firm extended the manufacturer’s expiration date for CharaExo lots by one year or more without supporting data. This false or misleading representation about your CharaExo product on your labeling causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. § 352(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your responses, received on September 1, 2024 and December 23, 2024,\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> to FDA’s Form FDA-483 in detail. Your responses are inadequate to address the violations noted above and on the Form FDA-483. While you assert that your products were manufactured according to section 361 of the PHS Act, the evidence collected shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act.\u003C\u002Fp>\u003Cp>We acknowledge that you state in your September and December 2024 responses that, “Chara Biologics is not [now], nor has it ever been a Stem Cell processor\u002Fmanufacturer.” We also acknowledge that you state in your December 2024 response that an agreement has been made with “the manufacturers to label all products prior to coming into the building.” Be advised that manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products. See 21 CFR 210.3(b)(12)\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and 1271.3(e). Based on your responses, it appears that Chara continues to package, store, and distribute drug products. For the reasons described above, Chara Biologics is a manufacturer subject to applicable CGMP requirements. This is consistent with your signed affidavit from the inspection, in which you state, “Chara Biologics, Inc. – This is the primary manufacturing entity for the Chara products CharaCore, CharaExo and CharaOmni.”\u003C\u002Fp>\u003Cp>Be advised that Chara is responsible for ensuring its products are manufactured in compliance with CGMP. Drugs not manufactured in compliance with CGMP are adulterated. The FD&amp;C Act prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce.\u003C\u002Fp>\u003Cp>We refer you to the following document for additional information, \u003Cem>Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> (November 2016), found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry. Also, be advised that, under the CGMP regulations, a “quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.” 21 CFR 211.22(a).\u003C\u002Fp>\u003Cp>With respect to donor eligibility, you state in your response that your contract manufacturers determine donor eligibility for the HCT\u002FPs used for your products. However, you are required to retain the donor-eligibility determination of the tissue donors for products that remain in inventory at your facility or have been distributed and remain in the marketplace as required by 21 CFR 1271.55(d)(1)(iii).\u003C\u002Fp>\u003Cp>Your responses do not adequately address the status of your manufacturing and distribution operations or your specific plans for disposition of the inventory of CharaExo, CharaCore, and CharaOmni at your facility that were manufactured under the conditions described in this letter. This includes the disposition of finished product received from your contract manufacturers prior to being re-labeled by your firm. Further, your responses do not adequately describe actions you have taken or plan to take to address the impact of the above-described deficiencies on your distributed products that remain in the marketplace. Your responses do not address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>FDA has previously provided notice to you in a letter dated November 25, 2019, that based on a review of your website it appeared your firm was marketing a biological drug product (CharaCore) that does not qualify for any exception under 21 CFR 1271.15, as is also explained in this letter. Your response dated December 17, 2019, stated that you would remove all testimonials from your websites. However, a review of your various social media accounts, which are linked to your websites, revealed patient testimonials for Chara Biologics that describe treatment of various diseases and conditions. In addition, your March 13, 2020, response stated your intention to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, however your products are not the subject of an approved BLA, nor is there an IND in effect for any of them.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>We note that in addition to Chara Biologics, Inc., Dr. Kong also controls the American Academy of Integrative Cell Therapy, Inc. (AAICT), co-located at the same business address. These entities function together: Chara Biologics contracts with manufacturers to make its products, which Chara Biologics then relabels and distributes; and AAICT develops trainings, and training materials and protocols for Chara Biologics products, which are distributed with the products themselves.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your amniotic fluid product, CharaExo, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because CharaCore and CharaOmni fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products per 21 CFR 210.3(b)(12).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your written responses are dated August 26, 2024, October 14, 2024, November 13, 2024, and December 18, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See footnote 4.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER-25-698004\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoy Kong, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nChara Biologics, Inc.\n\n9568 Topanga Canyon Blvd., Suite 104\n\nChatsworth, CA 91311\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nJanuary 17, 2025\nCBER 25-698004\nDear Dr. Kong:\nThe United States Food and Drug Administration (FDA) inspected your facility, Chara Biologics, Inc., located at the above address, between July 23, 2024, and August 16, 2024. During the inspection, FDA documented that Chara Biologics, Inc. (“you”) manufactures and distributes a human amniotic fluid product, CharaExo, as well as cellular products derived from human umbilical cord, CharaCore and CharaOmni, for allogeneic use (collectively, “your products”).1\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Your firm is responsible for ensuring that your products comply with CGMP requirements regardless of who manufactures, processes, packs, or holds them. This letter also explains you are in violation of current good tissue practice (CGTP) requirements set forth in 21 CFR part 1271 in the manufacture of your CharaCore and CharaOmni products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Furthermore, CharaExo is also misbranded under sections 502(a) of the FD&C Act, 21 U.S.C. § 352(a). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans. For example:\n• CharaExo\no Chara Biologics’ brochure, “Let the Joy of Healing Begin,” tells prospective customers to choose its products because “Chara offers the most comprehensive stem cell product CharaCore and high potency growth factor\u002Fextracellular vesicle product CharaExo.” It explains that “stem cells have been shown to have clinical benefits in” a long list of conditions including various autoimmune disorders, “neurodegenerative conditions (Parkinson’s, Alzheimers, Multiple Sclerosis, ALS, etc.)”, diabetes, cardiovascular and lung diseases, autism, spinal cord injuries, and cirrhosis. It also explains stem cell treatment can benefit its audience by reducing inflammation, improving immune function, and enhancing tissue repair.\no AAICT “Exosome Protocols” provide sample CharaExo dosing for the following diseases or conditions: Infertility, Osteoporosis, Diabetes, Autism, Cardiac, Renal, Hepatic, Pulmonary conditions, etc…. Musculoskeletal…Shoulder\u002FHip\u002FKnees…Ligaments\u002FTendons\u002FMeniscus \u002FLabrum… Elbow\u002FWrist\u002FAnkle\u002FFingers… Spine…Erectile Dysfunction… Female Urinary Incontinence…Autoimmune Diseases… Neuropathy… CNS Disease… Wound, Ulcers & Burns…” These protocols, which are part of AAICT’s Fundamentals of Stem Cell Practice course, accompany Chara Biologics’ CharaExo products when Chara Biologics sells them to physicians as part of Starter Package 3.\no Chara Biologics’ “FAQs for Physicians,” which you said you provide all your purchasing physicians, explains: “CharaExo also contains larger extracellular vesicles, as well as concentrated growth factors from amniotic fluid… Extracellular vesicles contain proteins, microRNAs and lipids, and all eukaryotic cells secrete and take up these nanoparticles, and they are a means of communication between cells. These nanoparticles have been increasingly recognized as playing an important role as the mediator of many of the MSC-associated therapeutic benefits. They can be quite useful therapeutically, as they may elicit a more immediate therapeutic response, although the benefits tend to be shorter-lasting than that of cell therapy.”\n• CharaCore\no Statements in Chara Biologics’ “Let the Joy of Healing Begin” brochure (discussed above)\no Chara Biologics’ FAQ for Physicians includes the following statements:\n “CharaCore® is highly rich in MSC’s…MSC’s: have anti-microbial properties, helpful in fighting acute, chronic or systemic infections… shown to be effective against protozoa (as in Lyme disease)”\n “How Can CharaCore help my patients? REGULATE INFLAMMATION, SCARRING & PAIN Birth tissue products have been shown to reduce inflammation, fibrous tissue growth, and potential scar tissue formation.”\n “How Can CharaCore help my patients? ANTI-MICROBIAL Application of birth tissue products has been shown to reduce bacteria counts in the wound…”\n• CharaOmni\no Chara Biologics’ FAQ for Physicians and CharaOmni promotional brochure state: “[W]hat set[s] CharaOmni apart from all other skincare products on the market: 1) Regenerative Stem Cell Components… Wharton’s Jelly Extract… reduces scar formation, and enhances wound healing…. Amniotic Extracellular Matrix - possesses powerful anti-inflammatory...properties.”\no Your website at www.charaomni.com explains “The stem cell regenerative elements in CharaOmni… have been known to provide crucial and powerful growth factors, extracellular matrix, as well as other cell signaling molecules that highly beneficial in skin repair and regeneration.”\n• Chara Biologics also promotes its products for the following diseases at www.charabiologics.com\u002Fscience, which links to https:\u002F\u002Faaict.org\u002Fclinical-evidence\u002F:\no “…Alzheimer’s…Asthma…Autism…Chronic Pain…COPD…Crohn’s Disease…Degenerative Disc Disease…Heart Disease…Kidney Failure…Liver Cirrhosis…Lupus…Macular Degeneration…Migraines & Tension Headache…Multiple Sclerosis…Nerve Injury…Osteoarthritis… Osteoporosis…Parkinson’s…”\nTherefore, CharaExo, CharaCore, and CharaOmni are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour CharaCore and CharaOmni products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264.2 HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, Chara Biologics, Inc. does not qualify for any exception in 21 CFR 1271.15, and your CharaCore and CharaOmni products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your CharaCore and CharaOmni products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into a flowable form significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your CharaCore and CharaOmni products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). These products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit). Rather, these products are intended for use in the treatment of a number of diseases and conditions listed above, which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your CharaCore and CharaOmni products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA, nor is there an investigational new drug application (IND) in effect for any of them.\nCGMP and\u002For CGTP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP and CGTP violations. At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483). FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe violations applicable to your products include, but are not limited to, the following:\n1. Your firm failed to establish a quality unit with the responsibility and authority to approve or reject all labeling and drug products, and the responsibilities and procedures applicable to the quality control unit are not in writing and followed, as required by 21 CFR 211.22(a) and 211.22(d).\nYour firm is a manufacturer subject to CGMP requirements. See 21 CFR 210.3(b)(12). For example, at the time of the inspection, your firm relabeled, stored, and distributed CharaCore and stored and distributed CharaOmni.4\nAn adequate quality unit overseeing all elements of CGMP is necessary to ensure drug products are consistently manufactured in compliance with CGMP and meet established specifications for identity, strength, quality and purity. However, your firm does not receive documentation, such as production records or test results, for each lot received for approval or rejection by your firm before distribution. Additionally, your firm has not established responsibilities and procedures applicable to the quality unit such as the following:\na. Laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b))\nb. Written procedures for production and process control designed to assure drug products have the identity, strength, quality, and purity purported or represented to possess (21 CFR 211.100(a))\nc. Review and approval of drug product production and control records, including those for packaging and labeling, to determine compliance with all established, approved written procedures before a batch is released or distributed (21 CFR 211.192)\nd. Written procedures describing the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a))\ne. Written procedures designed to assure that correct labels, labeling, and packaging are used (21 CFR 211.130)\n2. Documentation of the donor-eligibility determination, including the name of the responsible person who made the determination and the date of the determination, was not maintained, as required by 21 CFR 1271.55(d)(1)(iii).\nSpecifically, Chara did not maintain documentation of the donor eligibility determination, including the name of the responsible person who made the determination and the date of the determination, for donors of umbilical cord. Umbilical cord is used to manufacture CharaCore, which is used to manufacture CharaOmni.\nMisbranding Violation\nYour CharaExo product is also misbranded under section 502(a) of the FD&C Act, 21 U.S.C. § 352(a), because your labeling is false or misleading. Specifically, your firm extended the manufacturer’s expiration date for CharaExo lots by one year or more without supporting data. This false or misleading representation about your CharaExo product on your labeling causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. § 352(a).\nResponse to the Form FDA-483\nWe have reviewed your responses, received on September 1, 2024 and December 23, 2024,5 to FDA’s Form FDA-483 in detail. Your responses are inadequate to address the violations noted above and on the Form FDA-483. While you assert that your products were manufactured according to section 361 of the PHS Act, the evidence collected shows that your products do not meet the relevant criteria to be regulated solely under section 361 of the PHS Act.\nWe acknowledge that you state in your September and December 2024 responses that, “Chara Biologics is not [now], nor has it ever been a Stem Cell processor\u002Fmanufacturer.” We also acknowledge that you state in your December 2024 response that an agreement has been made with “the manufacturers to label all products prior to coming into the building.” Be advised that manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products. See 21 CFR 210.3(b)(12)6 and 1271.3(e). Based on your responses, it appears that Chara continues to package, store, and distribute drug products. For the reasons described above, Chara Biologics is a manufacturer subject to applicable CGMP requirements. This is consistent with your signed affidavit from the inspection, in which you state, “Chara Biologics, Inc. – This is the primary manufacturing entity for the Chara products CharaCore, CharaExo and CharaOmni.”\nBe advised that Chara is responsible for ensuring its products are manufactured in compliance with CGMP. Drugs not manufactured in compliance with CGMP are adulterated. The FD&C Act prohibits any person from introducing or delivering for introduction an adulterated or misbranded drug into interstate commerce.\nWe refer you to the following document for additional information, Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016), found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry. Also, be advised that, under the CGMP regulations, a “quality control unit shall be responsible for approving or rejecting drug products manufactured, processed, packed, or held under contract by another company.” 21 CFR 211.22(a).\nWith respect to donor eligibility, you state in your response that your contract manufacturers determine donor eligibility for the HCT\u002FPs used for your products. However, you are required to retain the donor-eligibility determination of the tissue donors for products that remain in inventory at your facility or have been distributed and remain in the marketplace as required by 21 CFR 1271.55(d)(1)(iii).\nYour responses do not adequately address the status of your manufacturing and distribution operations or your specific plans for disposition of the inventory of CharaExo, CharaCore, and CharaOmni at your facility that were manufactured under the conditions described in this letter. This includes the disposition of finished product received from your contract manufacturers prior to being re-labeled by your firm. Further, your responses do not adequately describe actions you have taken or plan to take to address the impact of the above-described deficiencies on your distributed products that remain in the marketplace. Your responses do not address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nFDA has previously provided notice to you in a letter dated November 25, 2019, that based on a review of your website it appeared your firm was marketing a biological drug product (CharaCore) that does not qualify for any exception under 21 CFR 1271.15, as is also explained in this letter. Your response dated December 17, 2019, stated that you would remove all testimonials from your websites. However, a review of your various social media accounts, which are linked to your websites, revealed patient testimonials for Chara Biologics that describe treatment of various diseases and conditions. In addition, your March 13, 2020, response stated your intention to (b)(4), however your products are not the subject of an approved BLA, nor is there an IND in effect for any of them.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n_________________________\n1 We note that in addition to Chara Biologics, Inc., Dr. Kong also controls the American Academy of Integrative Cell Therapy, Inc. (AAICT), co-located at the same business address. These entities function together: Chara Biologics contracts with manufacturers to make its products, which Chara Biologics then relabels and distributes; and AAICT develops trainings, and training materials and protocols for Chara Biologics products, which are distributed with the products themselves.\n2 We note that your amniotic fluid product, CharaExo, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\n3 Because CharaCore and CharaOmni fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all criteria in 21 CFR 1271.10(a).\n4 Manufacture, processing, packing, or holding of a drug product includes packaging and labeling operations, testing, and quality control of drug products per 21 CFR 210.3(b)(12).\n5 Your written responses are dated August 26, 2024, October 14, 2024, November 13, 2024, and December 18, 2024.\n6 See footnote 4.","Chara Biologics, Inc.","chara-biologics-inc-698004-01172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchara-biologics-inc-698004-01172025","2026-10-26T08:08:13.826296+00:00","2025-01-28","698004","Joy Kong, M.D.","2026-08-19T17:03:19.707+00:00","VIA UPS and Electronic Mail","CBER-25-698004","2025-01-17",{"id":98,"raw":99,"subject":104,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":113,"posted_date":114,"marcs_cms_no":115,"product_type":26,"closeout_date":116,"issuing_office":117,"recipient_name":118,"body_fetched_at":119,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":120,"medical_device_id":19,"response_letter_date":19},1988,[100,101,102,103,104,13,105,13],"\u003Ctime datetime=\"2023-07-18T13:20:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-27T04:00:00Z\">06\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-06272023\">Edge Biologicals Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations Central ","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-02232026\">\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Walter C. Edge Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Edge Biologicals Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>635 North 3rd Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Memphis\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations Central \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 660003\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 27, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Edge:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Memphis, TN on March 20, 2023 through April 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class I and class II in vitro diagnostics (IVDs) for medical applications. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Walter C. Edge Jr, President, dated 04\u002F05\u002F2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations. The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>A). You failed to validate the cleaning process for controlled environmental areas used for the aseptic processing of Mueller Hinton Agar antimicrobial susceptibility test culture media and other culture media devices.\u003C\u002Fp>\n\n\u003Cp>B). You failed to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of tubing sets used in aseptic fill operations for culture media devices.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response does not ensure that processes whose results cannot be fully verified with subsequent inspection are validated.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish procedures for corrective and preventative actions, as required by 820.100(a). For example,\u003C\u002Fp>\n\n\u003Cp>A). You failed to analyze sources of quality data to identify existing and potential causes of nonconforming product or other quality problems. Analysis of quality data from 2019-2022 does not include data from product quality investigations, incoming inspection rejects, or audits as required by your procedure, QMS-005\u002FJ, Corrective and Preventive Action. Furthermore, your firm does not conduct analysis of environmental monitoring data for aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>B). Your firm failed to adequately investigate and identify actions needed to correct and prevent the recurrence of product sterility failures of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified on 04\u002F29\u002F2021 and Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified on 05\u002F07\u002F2021, as required by your procedure QA-008\u002FL, Product\u002FProcess Quality Incidents (PQI’s).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response does not address requirements needed to ensure the causes of nonconformities relating to product, processes, and the quality system will be investigated, and actions will be taken to correct and prevent the recurrence.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish procedures and maintain requirements that must be met by suppliers, contractors, and consultants, as required by 820.50(a). For example, your firm purchases components and services critical to product quality; however, you failed to evaluate suppliers on their abilities to meet specific requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>4. Failure to maintain a device master record, as required by 21 CFR 820.181. For example, your firm failed to demonstrate that the Mueller Hinton Agar was manufactured according to the Device Master Record (DMR). Your quality manager could not locate the DMR to ensure the device production record (DHR) for each batch or lot of the Mueller Hinton Agar met specifications, including specifications for manufacturing, label requirements, and testing.\u003Cbr>\n\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). For example, your firm failed to implement the procedure 003-007, Environmental Monitoring, revised on 02\u002F26\u002F2021. Updates made to Attachment’s A, B, and H located within the procedure 003-007 were not implemented within the facility. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Mueller Hinton Agar, and other culture media is manufactured each day in controlled area which are not monitored as specified in your Environmental Monitoring procedure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80(a). You did not ensure that product is controlled until required acceptance activities have been completed and final release is authorized. In-process, nonconforming, and released IVD products were observed throughout production and storage areas without any indication of acceptance status. For example, testing media (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was observed stored in the employee breakroom refrigerator with food items.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2015 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>7. Failure to conduct quality audits to determine whether the quality system activities and results comply with quality system procedures, as required by 21 CFR 820.22. From 2013 to 2019 your firm failed to conduct quality audits as required per QMS-003\u002FL, Quality System Internal Audit Program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>8. Failure to ensure that personnel have necessary training and experience to perform their jobs, as required by 21 CFR 820.25(a). You failed to document adequate training as required by your procedure MAN-005\u002FI, EBI Employee Training. Five out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> production employees have no documented training records and no annual training on the quality system regulations has been documented for any employee.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2015 and 2018 inspections***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined where no documents were provided for review. Your firm’s response promised to implement corrective actions however the response was not comprehensive to address the systemic deficiencies identified including a corrective action plan and corrective actions to address the concerns along with timeframes to correct them.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – 12\u002F27\u002F2023\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – 12\u002F27\u002F2024 and 12\u002F27\u002F2025\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa I. Michurski, Director, Compliance Branch, via e-mail correspondence to ORADevices2FirmResponse@fda.hhs.gov. Refer to the Unique Identification Number (CMS Case # 660003) when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, via email at Ashley.mutawakkil@fda.hhs.gov or by phone at 305-816-1432.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological\u003Cbr>\nHealth\u003Cbr>\nDivision 2 – Central\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nWalter C. Edge Jr.\n\nRecipient Title\n\nPresident\n\nEdge Biologicals Inc.\n\n635 North 3rd Street\n\nMemphis, TN 38107\n\nUnited States\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations Central\n\nUnited States\n\nWARNING LETTER\n\nCMS# 660003\n\nJune 27, 2023\n\nDear Mr. Edge:\n\nDuring an inspection of your firm located in Memphis, TN on March 20, 2023 through April 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class I and class II in vitro diagnostics (IVDs) for medical applications. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Walter C. Edge Jr, President, dated 04\u002F05\u002F2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations. The violations include, but are not limited to, the following:\n\n1. Failure to validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 820.75(a). For example:\n\nA). You failed to validate the cleaning process for controlled environmental areas used for the aseptic processing of Mueller Hinton Agar antimicrobial susceptibility test culture media and other culture media devices.\n\nB). You failed to validate the (b)(4) sterilization of tubing sets used in aseptic fill operations for culture media devices.\n\n***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\n\nYour response does not ensure that processes whose results cannot be fully verified with subsequent inspection are validated.\n\n2. Failure to adequately establish procedures for corrective and preventative actions, as required by 820.100(a). For example,\n\nA). You failed to analyze sources of quality data to identify existing and potential causes of nonconforming product or other quality problems. Analysis of quality data from 2019-2022 does not include data from product quality investigations, incoming inspection rejects, or audits as required by your procedure, QMS-005\u002FJ, Corrective and Preventive Action. Furthermore, your firm does not conduct analysis of environmental monitoring data for aseptic processing operations.\n\nB). Your firm failed to adequately investigate and identify actions needed to correct and prevent the recurrence of product sterility failures of (b)(4), Lot (b)(4), identified on 04\u002F29\u002F2021 and Lot (b)(4), identified on 05\u002F07\u002F2021, as required by your procedure QA-008\u002FL, Product\u002FProcess Quality Incidents (PQI’s).\n\n***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\n\nYour response does not address requirements needed to ensure the causes of nonconformities relating to product, processes, and the quality system will be investigated, and actions will be taken to correct and prevent the recurrence.\n\n3. Failure to adequately establish procedures and maintain requirements that must be met by suppliers, contractors, and consultants, as required by 820.50(a). For example, your firm purchases components and services critical to product quality; however, you failed to evaluate suppliers on their abilities to meet specific requirements.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n4. Failure to maintain a device master record, as required by 21 CFR 820.181. For example, your firm failed to demonstrate that the Mueller Hinton Agar was manufactured according to the Device Master Record (DMR). Your quality manager could not locate the DMR to ensure the device production record (DHR) for each batch or lot of the Mueller Hinton Agar met specifications, including specifications for manufacturing, label requirements, and testing.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n5. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). For example, your firm failed to implement the procedure 003-007, Environmental Monitoring, revised on 02\u002F26\u002F2021. Updates made to Attachment’s A, B, and H located within the procedure 003-007 were not implemented within the facility. (b)(4), Mueller Hinton Agar, and other culture media is manufactured each day in controlled area which are not monitored as specified in your Environmental Monitoring procedure.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n6. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80(a). You did not ensure that product is controlled until required acceptance activities have been completed and final release is authorized. In-process, nonconforming, and released IVD products were observed throughout production and storage areas without any indication of acceptance status. For example, testing media ((b)(4)) was observed stored in the employee breakroom refrigerator with food items.\n\n***This is a repeat observation cited during the 2015 inspection***\n\n7. Failure to conduct quality audits to determine whether the quality system activities and results comply with quality system procedures, as required by 21 CFR 820.22. From 2013 to 2019 your firm failed to conduct quality audits as required per QMS-003\u002FL, Quality System Internal Audit Program.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n8. Failure to ensure that personnel have necessary training and experience to perform their jobs, as required by 21 CFR 820.25(a). You failed to document adequate training as required by your procedure MAN-005\u002FI, EBI Employee Training. Five out of (b)(4) production employees have no documented training records and no annual training on the quality system regulations has been documented for any employee.\n\n***This is a repeat observation cited during the 2015 and 2018 inspections***\n\nThe adequacy of your firm’s response cannot be determined where no documents were provided for review. Your firm’s response promised to implement corrective actions however the response was not comprehensive to address the systemic deficiencies identified including a corrective action plan and corrective actions to address the concerns along with timeframes to correct them.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – 12\u002F27\u002F2023\n\nSubsequent certifications – 12\u002F27\u002F2024 and 12\u002F27\u002F2025\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa I. Michurski, Director, Compliance Branch, via e-mail correspondence to ORADevices2FirmResponse@fda.hhs.gov. Refer to the Unique Identification Number (CMS Case # 660003) when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, via email at Ashley.mutawakkil@fda.hhs.gov or by phone at 305-816-1432.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBlake Bevill, MS\n\nProgram Division Director\n\nOffice of Medical Device and Radiological\n\nHealth\n\nDivision 2 – Central","Edge Biologicals Inc.","edge-biologicals-inc-660003-06272023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-06272023","2026-10-26T08:08:31.392911+00:00","Closed Out","2023-07-18","660003","2026-03-03","Division of Medical Device and Radiological Health Operations Central","Walter C. Edge Jr.","2026-08-20T00:52:33.091+00:00","2023-06-27",{"id":122,"raw":123,"subject":61,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":66,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":71,"closeout_date":19,"issuing_office":127,"recipient_name":137,"body_fetched_at":138,"delivery_method":139,"recipient_title":19,"reference_number":140,"action_taken_date":141,"medical_device_id":19,"response_letter_date":19},696,[124,125,126,127,128,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025\">Platinum Biologics LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-705090\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Beeben Russell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman of the Board \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Platinum Biologics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1510 E Colonial Drive, Suite 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@platinumbiologics.com\"> support@platinumbiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 2025\u003C\u002Fp>\u003Cp>CBER 25-705090\u003C\u002Fp>\u003Cp>Dear Mr. Russell:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.&nbsp;\u003C\u002Fp>\u003Cp>Your exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.&nbsp;\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Stephen Mesa\u003Cbr>Co-Founder\u003Cbr>Platinum Biologics, LLC\u003Cbr>1510 E. Colonial Drive, Suite 100\u003Cbr>Orlando, FL 32803\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&amp;C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-705090\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nBeeben Russell\n\nRecipient Title\n\nChairman of the Board\n\nPlatinum Biologics LLC\n\n1510 E Colonial Drive, Suite 103\n\nOrlando, FL 32803\n\nUnited States\n\nsupport@platinumbiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nAugust 15, 2025\nCBER 25-705090\nDear Mr. Russell:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).1 This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nSpecifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc:\nStephen Mesa\nCo-Founder\nPlatinum Biologics, LLC\n1510 E. Colonial Drive, Suite 100\nOrlando, FL 32803\n__________________\n1 We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\n2 Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Platinum Biologics LLC","platinum-biologics-llc-705090-08152025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025","2026-10-26T08:09:42.645343+00:00","2025-08-26","705090","Beeben Russell","2026-08-19T16:29:05.979+00:00","Via UPS and EMAIL","CBER 25-705090","2025-08-15",{"id":143,"raw":144,"subject":149,"body_html":150,"body_text":151,"firm_name":152,"letter_id":153,"created_at":18,"fei_number":19,"letter_url":154,"updated_at":155,"action_type":22,"case_status":23,"posted_date":156,"marcs_cms_no":157,"product_type":158,"closeout_date":19,"issuing_office":127,"recipient_name":159,"body_fetched_at":160,"delivery_method":161,"recipient_title":19,"reference_number":162,"action_taken_date":163,"medical_device_id":19,"response_letter_date":19},1165,[145,146,147,127,148,13,13,13],"\u003Ctime datetime=\"2024-11-19T14:20:00Z\">11\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-01T04:00:00Z\">11\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrontier-biologics-llc-686059-11012024\">Frontier Biologics, LLC\u003C\u002Fa>","Unapproved New Drug\u002FUnlicensed Biological Product Violations\u003Cbr \u002F>\r\n","Unapproved New Drug\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-686059\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chad W. Justice\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FFounder \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Frontier Biologics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>720 Jewell Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waco\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76712\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Chad@FrontierBiologics.com\"> Chad@FrontierBiologics.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 1, 2024&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25-686059\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Justice:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address between February 27, 2024, and March 8, 2024. During the inspection, FDA documented that your company manufactures a human amniotic fluid derived product, Purified Fluid Allograft, as well as a human amniotic membrane derived product, Allograft Matrix, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for wound healing, to lower inflammation, or for orthopedic use, as evidenced by the following statements in materials collected during the inspection:\u003C\u002Fp>\u003Cul>\u003Cli>“Purified Amniotic Fluid Allograft…can be applied directly at the site of injury, pain, or inflammation with a simple injection…Once introduced, it causes a systemic healing cascade in the body, targeting the site of injection.”\u003C\u002Fli>\u003Cli>“[Purified Amniotic Fluid Allograft] Applications [include]:\u003Cbr>o Muscle Tears\u003Cbr>o Soft Tissue Injuries\u003Cbr>o Wounds, Acute and Chronic\u003Cbr>o Osteoarthritis\u003Cbr>o Joint Injuries \u002F Pain”\u003C\u002Fli>\u003Cli>“Allograft [Matrix]…Benefits:\u003Cbr>o Catalyzes natural healing process to support proper remodeling\u003Cbr>o Provides specific signaling which lowers the body’s inflammatory response\u003Cbr>o Mitigates formation of scar tissue”\u003C\u002Fli>\u003Cli>“Allograft [Matrix]…Use:\u003Cbr>o … assists in wound healing, both chronic and acute.\u003Cbr>o … is used to enhance healing after a primary surgical repair.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your Allograft Matrix product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Allograft Matrix product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a barrier for amniotic membrane). Rather, your product is intended for use in catalyzing wound healing and reducing inflammation, which is not a basic function of amniotic membrane in the donor.\u003C\u002Fp>\u003Cp>Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, you failed to adequately validate (i.e., by performing media fill simulations) the aseptic process used to manufacture your Purified Fluid Allograft product. Your product purports to be sterile and is expected to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> Specifically,\u003C\u002Fp>\u003Cp>a. The manufacturing process for your Purified Fluid Allograft product has not been adequately validated with respect to identity, strength, quality, and purity. During the inspection, you provided a validation study for your amniotic fluid product, which only tested for sterility. However, this is not sufficient to assure the identity, strength, quality, and purity of your product.\u003C\u002Fp>\u003Cp>b. The manufacturing process for your Allograft Matrix product has not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv).\u003C\u002Fstrong> For example, you have not performed non-viable particulate monitoring, personnel monitoring, active or passive viable air sampling, or sampling of critical surfaces for microorganisms in the aseptic processing area in association with each production batch.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, you have not validated your process for cleaning and disinfecting the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanrooms where your products are manufactured.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Written records are not always made of investigations into unexplained discrepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed , as required by 21 CFR 211.192.\u003C\u002Fstrong> For example, from March 2023 and June 2023, your firm had two sterility failures during finished product testing of your Purified Fluid Allograft product. Although you identified the contaminating organisms, you failed to conduct an investigation to determine the root cause of the failures.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a).\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date to your products without supporting data.\u003C\u002Fp>\u003Cp>\u003Cstrong>Response to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your response, dated March 28, 2024, to FDA’s Form FDA-483 in detail. Your response is inadequate because it did not provide sufficient detail for FDA to fully assess the adequacy of your corrective actions. It lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, in your response, you note that going forward, any vials still in house from previously opened lots will be discarded. However, your response does not address the rubber stoppers and metal caps, which are used as packaging for your finished amniotic fluid products, that are \u003Cstrong>(b)(4)\u003C\u002Fstrong> using a sterilization process that has not been validated. Please be advised that in accordance with 21 CFR 211.113(b), you are required to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of sterilization processes.\u003C\u002Fp>\u003Cp>Your response also does not address your specific plans for disposition of the inventory of Purified Fluid Allograft or Allograft Matrix at your facility that were manufactured under the conditions described in this letter. Further, your response does not address products that have been distributed and remain in the marketplace.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to voluntarily suspend production activities until you have made corrections to the observations listed on the Form FDA-483. However, your response does not adequately address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use. 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> At the time of the inspection, FDA collected evidence that your human amniotic fluid derived product is also referred to as “Evexcell™ Purified Nanoparticle Fluid,” “Purified Amniotic Fluid Allograft,” “Purified Amniotic Fluid,” “Trophic Fluid Allograft,” “Trophic Factor Amniotic Fluid,” “Trophic Factor Purified Fluid Allograft,” and “Cryovial”. FDA also collected evidence that your human amniotic membrane derived product is also referred to as “Allograft Patch,” “Dual Layer Allograft Matrix,” “Dual Layer Allograft Patch,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “Patch Matrix,” “Matrix,” “Amniotic Membrane,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Allograft Patch,” and “Membrane.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that your amniotic fluid product, Purified Fluid Allograft, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER 25-686059\n\nProduct:\n\nBiologics\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChad W. Justice\n\nRecipient Title\n\nPresident\u002FFounder\n\nFrontier Biologics, LLC\n\n720 Jewell Drive\n\nWaco, TX 76712\n\nUnited States\n\nChad@FrontierBiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nNovember 1, 2024\nCBER 25-686059\nDear Mr. Justice:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address between February 27, 2024, and March 8, 2024. During the inspection, FDA documented that your company manufactures a human amniotic fluid derived product, Purified Fluid Allograft, as well as a human amniotic membrane derived product, Allograft Matrix, for allogeneic use (collectively, “your products”).1\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for wound healing, to lower inflammation, or for orthopedic use, as evidenced by the following statements in materials collected during the inspection:\n“Purified Amniotic Fluid Allograft…can be applied directly at the site of injury, pain, or inflammation with a simple injection…Once introduced, it causes a systemic healing cascade in the body, targeting the site of injection.”\n“[Purified Amniotic Fluid Allograft] Applications [include]:\no Muscle Tears\no Soft Tissue Injuries\no Wounds, Acute and Chronic\no Osteoarthritis\no Joint Injuries \u002F Pain”\n“Allograft [Matrix]…Benefits:\no Catalyzes natural healing process to support proper remodeling\no Provides specific signaling which lowers the body’s inflammatory response\no Mitigates formation of scar tissue”\n“Allograft [Matrix]…Use:\no … assists in wound healing, both chronic and acute.\no … is used to enhance healing after a primary surgical repair.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).2\nYour Allograft Matrix product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your company does not qualify for any exception in 21 CFR 1271.15, and your product fails to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Allograft Matrix product fails to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a barrier for amniotic membrane). Rather, your product is intended for use in catalyzing wound healing and reducing inflammation, which is not a basic function of amniotic membrane in the donor.\nTherefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your product is regulated as a drug as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and a biological product as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspection of your facility documented evidence of significant CGMP violations. At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483).\nThe CGMP violations applicable to your products include, but are not limited to, the following:\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, you failed to adequately validate (i.e., by performing media fill simulations) the aseptic process used to manufacture your Purified Fluid Allograft product. Your product purports to be sterile and is expected to be sterile.\n2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess, as required by 21 CFR 211.100(a). Specifically,\na. The manufacturing process for your Purified Fluid Allograft product has not been adequately validated with respect to identity, strength, quality, and purity. During the inspection, you provided a validation study for your amniotic fluid product, which only tested for sterility. However, this is not sufficient to assure the identity, strength, quality, and purity of your product.\nb. The manufacturing process for your Allograft Matrix product has not been validated with respect to identity, strength, quality, and purity.\n3. Aseptic processing areas are deficient regarding the system for environmental monitoring to prevent contamination, as required by 21 CFR 211.42(c)(10)(iv). For example, you have not performed non-viable particulate monitoring, personnel monitoring, active or passive viable air sampling, or sampling of critical surfaces for microorganisms in the aseptic processing area in association with each production batch.\n4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, you have not validated your process for cleaning and disinfecting the ISO (b)(4) cleanrooms where your products are manufactured.\n5. Written records are not always made of investigations into unexplained discrepancies or the failure of a batch or any of its components to meet specifications whether or not the batch has already been distributed , as required by 21 CFR 211.192. For example, from March 2023 and June 2023, your firm had two sterility failures during finished product testing of your Purified Fluid Allograft product. Although you identified the contaminating organisms, you failed to conduct an investigation to determine the root cause of the failures.\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a). Specifically, you assigned a (b)(4) expiration date to your products without supporting data.\nResponse to the Form FDA-483\nWe have reviewed your response, dated March 28, 2024, to FDA’s Form FDA-483 in detail. Your response is inadequate because it did not provide sufficient detail for FDA to fully assess the adequacy of your corrective actions. It lacks documentation to demonstrate that you have corrected your violations and fails to include a timeline for completion of all necessary corrective actions. For example, in your response, you note that going forward, any vials still in house from previously opened lots will be discarded. However, your response does not address the rubber stoppers and metal caps, which are used as packaging for your finished amniotic fluid products, that are (b)(4) using a sterilization process that has not been validated. Please be advised that in accordance with 21 CFR 211.113(b), you are required to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of sterilization processes.\nYour response also does not address your specific plans for disposition of the inventory of Purified Fluid Allograft or Allograft Matrix at your facility that were manufactured under the conditions described in this letter. Further, your response does not address products that have been distributed and remain in the marketplace.\nWe acknowledge your commitment to voluntarily suspend production activities until you have made corrections to the observations listed on the Form FDA-483. However, your response does not adequately address your failure to have an IND in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect. 42 U.S.C. 262(a). Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use. 21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection are intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n_________________________\n1 At the time of the inspection, FDA collected evidence that your human amniotic fluid derived product is also referred to as “Evexcell™ Purified Nanoparticle Fluid,” “Purified Amniotic Fluid Allograft,” “Purified Amniotic Fluid,” “Trophic Fluid Allograft,” “Trophic Factor Amniotic Fluid,” “Trophic Factor Purified Fluid Allograft,” and “Cryovial”. FDA also collected evidence that your human amniotic membrane derived product is also referred to as “Allograft Patch,” “Dual Layer Allograft Matrix,” “Dual Layer Allograft Patch,” “(b)(4),” “Patch Matrix,” “Matrix,” “Amniotic Membrane,” “(b)(4) Allograft Patch,” and “Membrane.”\n2 We note that your amniotic fluid product, Purified Fluid Allograft, is not an HCT\u002FP because amniotic fluid is a secreted bodily fluid and the definition of HCT\u002FPs in 21 CFR 1271.3(d)(3) excludes secreted or extracted human products.\n3 Because your product fails to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Frontier Biologics, LLC","frontier-biologics-llc-686059-11012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffrontier-biologics-llc-686059-11012024","2026-10-26T08:08:43.737712+00:00","2024-11-19","686059","BiologicsDrugs","Chad W. Justice","2026-08-19T18:14:09.235+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","CBER 25-686059","2024-11-01",{"id":165,"raw":166,"subject":61,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":110,"fei_number":19,"letter_url":176,"updated_at":177,"action_type":22,"case_status":113,"posted_date":178,"marcs_cms_no":179,"product_type":71,"closeout_date":180,"issuing_office":181,"recipient_name":182,"body_fetched_at":183,"delivery_method":74,"recipient_title":19,"reference_number":184,"action_taken_date":185,"medical_device_id":19,"response_letter_date":19},1821,[167,168,169,170,128,13,171,13],"\u003Ctime datetime=\"2023-09-29T21:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-18T04:00:00Z\">09\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023\">Signature Biologics, LLC\u003C\u002Fa>"," Division of Biological Products Operations II","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-02212025\">\u003Ctime datetime=\"2025-03-06T05:00:00Z\">03\u002F06\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 23-631039\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Neil H. Riordan, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Signature Biologics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4040 W. Royal Lane, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063-2844\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:neil@aidanresearch.com\"> neil@aidanresearch.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> #OBPO 23-631039\u003C\u002Fp>\n\n\u003Cp>September 18, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Riordan:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials per batch. However, from November 2018 through February 2020, your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> commercial batches of Signature Cord™ with \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for settling plate samples within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. \u003C\u002Fstrong>For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)].\u003C\u002Fstrong> For example, your firm failed to perform endotoxin testing as a release criterion on \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, the manufacturing process for your product has not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a two-year expiration date to your product without supporting data.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: Chloe R. Bailey, President and Chief Operating Officer\u003Cbr>\nSignature Biologics, LLC\u003Cbr>\n4040 W. Royal Lane, Suite 100\u003Cbr>\nIrving, TX 75063-2844\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup>, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that it discontinued their manufacture and distribution as of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is therefore FDA’s understanding that any previously manufactured Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature Cord\u003Csup>TM\u003C\u002Fsup> appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 23-631039\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nNeil H. Riordan, Ph.D.\n\nRecipient Title\n\nChief Executive Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\nUnited States\n\nneil@aidanresearch.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWarning Letter #OBPO 23-631039\n\nSeptember 18, 2023\n\nDear Dr. Riordan:\n\nDuring an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.1 You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.2\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over (b)(4) vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of (b)(4) vials per batch. However, from November 2018 through February 2020, your firm manufactured (b)(4) commercial batches of Signature Cord™ with (b)(4) vials.\n\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\n\na. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\n\nb. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: (b)(4) colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, (b)(4) CFUs for settling plate samples within the ISO 7 supporting cleanrooms, (b)(4) CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and (b)(4) CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\n\n3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\n\n4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)]. For example, your firm failed to perform endotoxin testing as a release criterion on (b)(4) units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\n\n5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, the manufacturing process for your product has not been validated.\n\n6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\n\n7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a two-year expiration date to your product without supporting data.\n\nFDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\n\nWe acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Chloe R. Bailey, President and Chief Operating Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\n_______________________\n\n1 During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature MatrixTM and Signature MatrixHXTM, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in (b)(4) and that it discontinued their manufacture and distribution as of (b)(4). It is therefore FDA’s understanding that any previously manufactured Signature MatrixTM and Signature MatrixHXTM products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature MatrixTM and Signature MatrixHXTM are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n2 We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature CordTM appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.","Signature Biologics, LLC","signature-biologics-llc-631039-09182023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023","2026-10-26T08:09:57.530976+00:00","2023-09-29","631039","2025-03-06","Division of Biological Products Operations II","Neil H. Riordan, Ph.D.","2026-08-20T00:38:15.637+00:00","OBPO 23-631039","2023-09-18",{"id":187,"raw":188,"subject":193,"body_html":194,"body_text":195,"firm_name":196,"letter_id":197,"created_at":43,"fei_number":19,"letter_url":198,"updated_at":199,"action_type":22,"case_status":23,"posted_date":200,"marcs_cms_no":201,"product_type":202,"closeout_date":19,"issuing_office":192,"recipient_name":203,"body_fetched_at":204,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":205,"medical_device_id":19,"response_letter_date":19},3229,[189,190,191,192,193,13,13,13],"\u003Ctime datetime=\"2021-08-04T14:00:00Z\">08\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-03T04:00:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-willow-biologics-613948-08032021\">Blue Willow Biologics\u003C\u002Fa>","Center for Drug Evaluation and Research","Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Chad Costley, MD\u002FMBA\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Blue Willow Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2311 Green Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ann Arbor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nanobio@bluewillow.com\"> nanobio@bluewillow.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: August 3, 2021\u003Cbr>\n\u003Cbr>\nRE: Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) had reviewed your websites at the Internet addresses https:\u002F\u002Fnanobioprotect.com and https:\u002F\u002Fbluewillow.com on March 24, 2021. The FDA observed that your websites offered a non-alcohol-based consumer antiseptic nasal product\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> for sale in the United States and that this product was intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and other conditions in people. FDA also observed that your product is for sale in the United States on other websites, including at https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fnanobio-protect-nasal-antiseptic-prodid-160333. Based on our review, this product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under sections 502(a) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce violated sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sold an unapproved and unauthorized product that was intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your product label that establish the intended use of your product (as defined in 21 CFR 201.128) and examples of the claims on your website that established the intended use of your product and misleadingly represented it as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>NanoBioProtect.com and Bluewillow.com websites and NanoBio Protect Nasal Antiseptic label:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>NanoBio® Protect Over-The-Counter Nasal Antiseptic Kills COVID-19 Virus in Lab Tests.” [from your website https:\u002F\u002Fbluewillow.com\u002F%ef%bb%bf%ef%bb%bfnanobio-protect-over-the-counter-nasal-antiseptic-kills-covid-19-virus-in-lab-tests\u002F]\u003C\u002Fli>\n\t\u003Cli>“Recent studies conducted by Public Health England also demonstrate NanoBio® Protect’s ability to kill COVID-19 virus in laboratory test.” [from your website https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect . . . Protects for up to 8 hours . . . Kills 99.99% of germs on contact . . . Reduces the risk of respiratory infection ….” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“KILLS GERMS THAT ENTER THE NOSE . . . PROTECTS FOR 8 HOURS . . .NEXT-LEVEL PROTECTION AGAINST INFECTION” [from your product label]\u003C\u002Fli>\n\t\u003Cli>“Get protection from infection that lasts all day.” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect offers next-level protection to help keep you and your family healthy. It is the only alcohol-free nasal antiseptic proven to kill 99.99% of infection-causing germs when applied to the skin in and around the nose. . . NanoBio Protect uses patented, natural-oil nanodroplets that deliver the antiseptic directly to the surface of germs, killing them on contact. Uniquely, the nanodroplets remain active on the skin after application for up to 8 hours (in lab testing), providing lasting protection against the germs that cause infection.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fli>\n\t\u003Cli>“NanoBio Protect adds BZK antiseptic to the surface of nanodroplets. This technology offers four distinct advantages over conventional BZK antiseptics:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The Nanodroplets optimize the ability of the antiseptic to kill germs. The droplets sit on skin after application, enabling protection for up to 8 hours (in lab testing) . . .” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Is NanoBio Protect US FDA regulated? Yes. NanoBio® Protect nasal antiseptic adheres to the OTC monograph system for topical skin antiseptics. In testing by independent FDA registered laboratories, NanoBio® Protect was shown to kill 99.99% of a broad spectrum of pathogenic organisms. To learn more, visit https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\u003C\u002Fp>\n\n\u003Cp>Based on the above claims, your topical antiseptic product is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, your product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NanoBio Protect Nasal Antiseptic Solution product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, your consumer topical antiseptic product does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>Specifically, your labeling claims suggesting and depicting that your topical antiseptic product is effective in preventing infection or disease go beyond merely describing the general intended use of consumer antiseptics as set forth in the 1994 TFM.5 Your claims on the product label, suggesting your consumer antiseptic provides all day efficacy against infection, and your claims on your websites, which suggested all day protection against serious-disease related pathogens including the novel coronavirus that causes COVID-19, do not conform to the 1994 TFM or any of the amendments to the TFM discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by creating a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, this product may have given users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who did not follow these interventions were at increased risk for contracting COVID-19 and for spreading disease if they had been exposed to the virus, thereby prolonging the pandemic, and increasing its associated morbidity and mortality. In addition, according to the product labeling, NanoBio Protect Nasal Antiseptic Solution is intended to be applied inside and around the nostrils. Consumer antiseptic products intended for administration inside and around the nostrils are not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>We are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your consumer topical antiseptic product is GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your consumer topical antiseptic product is a new drug under section 201(p) of the FD&amp;C Act. In addition, there are no FDA-approved applications in effect for your consumer topical antiseptic product and, accordingly, it is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your consumer topical antiseptic product also does not conform to any temporary policy FDA has implemented for alcohol-based hand sanitizer products during the public health emergency.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic product was also misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because the labeling was false or misleading. Specifically, labeling for this product claimed that the product “adheres to the OTC monograph system for topical skin antiseptics.” As noted above, this product does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>This consumer topical antiseptic products is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to prevent the recurrence of future violations. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act, with a notation that, as of the date of this letter, your firm’s listed products are no longer sold for the prevention, treatment, mitigation, diagnosis or cure of COVID-19. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products.Corrective actions taken to address the sale of your unapproved and unauthorized product for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have to be confirmed by the FDA, for the published list to be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the corrections. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your non-alcohol-based consumer antiseptic nasal product is NanoBio Protect Nasal Antiseptic Solution.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020 and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use of without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as the nose are not permitted.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because your consumer topical antiseptic product is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChad Costley, MD\u002FMBA\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nBlue Willow Biologics\n\n2311 Green Road\n\nAnn Arbor, MI 48105\n\nUnited States\n\nnanobio@bluewillow.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nDate: August 3, 2021\n\nRE: Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) had reviewed your websites at the Internet addresses https:\u002F\u002Fnanobioprotect.com and https:\u002F\u002Fbluewillow.com on March 24, 2021. The FDA observed that your websites offered a non-alcohol-based consumer antiseptic nasal product1 for sale in the United States and that this product was intended to mitigate, prevent, treat, diagnose, or cure COVID-192 and other conditions in people. FDA also observed that your product is for sale in the United States on other websites, including at https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fnanobio-protect-nasal-antiseptic-prodid-160333. Based on our review, this product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under sections 502(a) and (ee) of the FD&C Act, 21 U.S.C. 352(a) and (ee). Introduction or delivery for introduction of such a product into interstate commerce violated sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sold an unapproved and unauthorized product that was intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people.\n\nSome examples of the claims on your product label that establish the intended use of your product (as defined in 21 CFR 201.128) and examples of the claims on your website that established the intended use of your product and misleadingly represented it as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following:\n\nNanoBioProtect.com and Bluewillow.com websites and NanoBio Protect Nasal Antiseptic label:\n\nNanoBio® Protect Over-The-Counter Nasal Antiseptic Kills COVID-19 Virus in Lab Tests.” [from your website https:\u002F\u002Fbluewillow.com\u002F%ef%bb%bf%ef%bb%bfnanobio-protect-over-the-counter-nasal-antiseptic-kills-covid-19-virus-in-lab-tests\u002F]\n\n“Recent studies conducted by Public Health England also demonstrate NanoBio® Protect’s ability to kill COVID-19 virus in laboratory test.” [from your website https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F]\n\n“NanoBio Protect . . . Protects for up to 8 hours . . . Kills 99.99% of germs on contact . . . Reduces the risk of respiratory infection ….” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\n\n“KILLS GERMS THAT ENTER THE NOSE . . . PROTECTS FOR 8 HOURS . . .NEXT-LEVEL PROTECTION AGAINST INFECTION” [from your product label]\n\n“Get protection from infection that lasts all day.” [from your website https:\u002F\u002Fnanobioprotect.com\u002F]\n\n“NanoBio Protect offers next-level protection to help keep you and your family healthy. It is the only alcohol-free nasal antiseptic proven to kill 99.99% of infection-causing germs when applied to the skin in and around the nose. . . NanoBio Protect uses patented, natural-oil nanodroplets that deliver the antiseptic directly to the surface of germs, killing them on contact. Uniquely, the nanodroplets remain active on the skin after application for up to 8 hours (in lab testing), providing lasting protection against the germs that cause infection.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\n“NanoBio Protect adds BZK antiseptic to the surface of nanodroplets. This technology offers four distinct advantages over conventional BZK antiseptics:\n\nThe Nanodroplets optimize the ability of the antiseptic to kill germs. The droplets sit on skin after application, enabling protection for up to 8 hours (in lab testing) . . .” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\n“Is NanoBio Protect US FDA regulated? Yes. NanoBio® Protect nasal antiseptic adheres to the OTC monograph system for topical skin antiseptics. In testing by independent FDA registered laboratories, NanoBio® Protect was shown to kill 99.99% of a broad spectrum of pathogenic organisms. To learn more, visit https:\u002F\u002Fbluewillow.com\u002Fnanobio-protect\u002F.” [from your website https:\u002F\u002Fnanobioprotect.com\u002Ffrequently-asked-questions\u002F]\n\nWe note that, as of the date of this letter, some of the claims cited above appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\n\nBased on the above claims, your topical antiseptic product is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. § 321(g)(1)(B), because it is intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. § 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, your product is intended for use as a consumer topical antiseptic.\n\nThis consumer topical antiseptic is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your NanoBio Protect Nasal Antiseptic Solution product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, your consumer topical antiseptic product does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nSpecifically, your labeling claims suggesting and depicting that your topical antiseptic product is effective in preventing infection or disease go beyond merely describing the general intended use of consumer antiseptics as set forth in the 1994 TFM.5 Your claims on the product label, suggesting your consumer antiseptic provides all day efficacy against infection, and your claims on your websites, which suggested all day protection against serious-disease related pathogens including the novel coronavirus that causes COVID-19, do not conform to the 1994 TFM or any of the amendments to the TFM discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by creating a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, this product may have given users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who did not follow these interventions were at increased risk for contracting COVID-19 and for spreading disease if they had been exposed to the virus, thereby prolonging the pandemic, and increasing its associated morbidity and mortality. In addition, according to the product labeling, NanoBio Protect Nasal Antiseptic Solution is intended to be applied inside and around the nostrils. Consumer antiseptic products intended for administration inside and around the nostrils are not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule6.\n\nWe are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your consumer topical antiseptic product is GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your consumer topical antiseptic product is a new drug under section 201(p) of the FD&C Act. In addition, there are no FDA-approved applications in effect for your consumer topical antiseptic product and, accordingly, it is an unapproved new drug sold in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your consumer topical antiseptic product also does not conform to any temporary policy FDA has implemented for alcohol-based hand sanitizer products during the public health emergency.7\n\nThis consumer topical antiseptic product was also misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because the labeling was false or misleading. Specifically, labeling for this product claimed that the product “adheres to the OTC monograph system for topical skin antiseptics.” As noted above, this product does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nThis consumer topical antiseptic products is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to prevent the recurrence of future violations. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure, and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act, with a notation that, as of the date of this letter, your firm’s listed products are no longer sold for the prevention, treatment, mitigation, diagnosis or cure of COVID-19. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products.Corrective actions taken to address the sale of your unapproved and unauthorized product for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have to be confirmed by the FDA, for the published list to be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within which you will complete the corrections. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_______________________________\n\n1 Your non-alcohol-based consumer antiseptic nasal product is NanoBio Protect Nasal Antiseptic Solution.\n\n2 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020 and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak. (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n5 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\n\n6 The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use of without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as the nose are not permitted.\n\n7 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because your consumer topical antiseptic product is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Blue Willow Biologics","blue-willow-biologics-613948-08032021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fblue-willow-biologics-613948-08032021","2026-10-26T08:08:06.851143+00:00","2021-08-04","613948","Drugs","Chad Costley, MD\u002FMBA","2026-08-20T02:43:44.258+00:00","2021-08-03",{"id":207,"raw":208,"subject":104,"body_html":212,"body_text":213,"firm_name":214,"letter_id":215,"created_at":216,"fei_number":19,"letter_url":217,"updated_at":218,"action_type":22,"case_status":23,"posted_date":219,"marcs_cms_no":220,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":221,"body_fetched_at":222,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":223,"medical_device_id":19,"response_letter_date":19},252,[209,210,211,11,104,13,13,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-24T05:00:00Z\">02\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026\">IsoTis OrthoBiologics, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Peter P. Nalbach\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Spine Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IsoTis OrthoBiologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Goodyear, Ste A,\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER&nbsp;\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #723370\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 24, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Nalbach:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\u003Cp>Your firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\u003C\u002Fp>\u003Cp>As part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\u003C\u002Fp>\u003Cp>Additionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination.\u003C\u002Fp>\u003Cp>Your firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination was no longer occurring during your demineralization process.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints determined to be relevant now that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\u003C\u002Fp>\u003Cp>2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. Two corrective actions were implemented:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\u003C\u002Fp>\u003Cp>Additionally, your firm determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection was sufficient to identify potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and required training of your demineralization team to \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspect the propellers, however your firm has not validated the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection process for the propeller blades to demonstrate it is sufficient in identifying potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection method with \u003Cstrong>(b)(4)\u003C\u002Fstrong> study, completing Installation Qualification for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\u003C\u002Fp>\u003Cul>\u003Cli>An evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate contamination is no longer occurring in production and that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" clearance is sufficient to prevent all contact under all operating conditions\u003C\u002Fli>\u003Cli>Testing has been performed to confirm absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in DBM\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates in finished product.\u003C\u002Fp>\u003Cp>Additionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\u003C\u002Fp>\u003Cp>3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>Your firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\u003C\u002Fp>\u003Cp>Your firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\u003C\u002Fp>\u003Cp>Your firm identified the propeller blade was potentially shedding \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. \u003Cstrong>(b)(4)\u003C\u002Fstrong> only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\u003C\u002Fp>\u003Cp>Additionally, your firm did not reevaluate the probability of occurrence for potential contaminants. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminants.\u003C\u002Fp>\u003Cp>According to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulates may have been present in your DBM, potentially impacting over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong>) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\u003C\u002Fp>\u003Cul>\u003Cli>Updated PMFEAs (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Updated Hazard Analysis HA-\u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Conducted a retrospective Health Hazard Evaluation (HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination occurred from 2008-2024, with over \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices potentially affected, however no actual testing was performed to confirm the absence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in distributed product. The HHE is deficient in that:\u003C\u002Fp>\u003Cul>\u003Cli>Your firm reviewed \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints and deemed \u003Cstrong>(b)(4)\u003C\u002Fstrong> clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints related to \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination without adequately documenting an investigation showing how they ruled out \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination as a contributing factor.\u003C\u002Fli>\u003Cli>Your firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles as typical post-surgical inflammation\u003C\u002Fli>\u003Cli>Severity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\u003C\u002Fli>\u003Cli>Biocompatibility has not been adequately evaluated. Your firm states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure is not expected to cause adverse effects. However, the cited devices use intact \u003Cstrong>(b)(4)\u003C\u002Fstrong> structures, not particulate contamination. Your firm provides no data demonstrating that they have:\u003Cbr>o Characterized potential particle generation during normal use and wear.\u003Cbr>o Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\u003Cbr>o Assessed the clinical significance of any particle elution through risk analysis.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “\u003Cstrong>CMS Case 723370\u003C\u002Fstrong>” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden&nbsp;&nbsp;\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPeter P. Nalbach\n\nRecipient Title\n\nVice President and General Manager of Spine Operations\n\nIsoTis OrthoBiologics, Inc.\n\n2 Goodyear, Ste A,\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #723370\nFebruary 24, 2026\nDear Mr. Nalbach:\nDuring an inspection of your firm located in Irvine, CA from October 6, 2025, through October 17, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures resorbable calcium salt bone void filler devices, branded under the Accell Family of products, to include the Accell Evo3c. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, your manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from your Director Quality Systems, dated November 7, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example:\nYour firm failed to adequately take action to correct the cause of nonconformities in order to prevent recurrence. Your firm's corrective and preventative action procedure, Corrective and Preventive Actions CP-1001 Rev. J Effective: 8\u002F22\u002F2022, requires your firm to perform an investigation, determine the need for containment, and assess the risk associated with the issue.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address potential (b)(4) particulate contamination occurring during the demineralization process of bone tissue, due to the propeller blade contacting the bottom of the demineralization vessel. The issue was discovered by a manufacturing engineer and documented in emails dating back to 06\u002F22\u002F2023.\nAs part of CAPA 157738, your firm conducted a risk assessment for the demineralization process. In your risk analysis document, PFMEA-011 Rev. 12, effective October 23, 2023, your firm identified (b)(4) as a risk for particulate contamination. This risk was assigned a severity rating of Moderate and a probability of Improbable, resulting in an overall Acceptable risk rating. Despite discovering that the propeller blade was potentially shedding (b)(4) particles during demineralization, your firm did not investigate whether this finding affected your risk probability rating. In CAPA 157738, your firm classified the risk as low without providing justification for this conclusion and determined that containment action was not required due to your determined low risk. Your firm's CAPA investigation and actions are inadequate because it did not assess the potential impact to finished devices, including distributed product.\nAdditionally, your firm’s Verification of Effectiveness included reviewing 18 work orders to confirm that visual inspection of the propeller was performed. The verification of effectiveness does not demonstrate that visual inspection of the propeller is sufficient to identify potential (b)(4) particulate in your firm's demineralized bone matrix (DBM). Your firm did not verify if the corrective actions performed were sufficient to correct the potential (b)(4) particulate contamination.\nYour firm closed CAPA 157738 on 12\u002F17\u002F2024 without evidence that (b)(4) particulate contamination was no longer occurring during your demineralization process.\nWe reviewed your firm’s response and conclude that it is not adequate. While your firm’s response acknowledges procedural deficiencies and proposes process improvements, the CAPA defers critical product risk elements to separate CAPAs without clear indication that all deficiencies identified in CAPA-157738 have been adequately addressed. For example, in HHE-(b)(4), your firm identified (b)(4) complaints determined to be relevant now that (b)(4) contamination has been identified as a potential contributing factor. However, none of the related CAPAs indicate whether an MDR assessment was performed for these complaints.\nAdditionally, it is not clear why the scope of the CAPA retrospective review is from 01\u002F01\u002F2022 to present.\n2. Failure to revalidate a validated process when changes or process deviations occurred, as required by 21 CFR 820.75(c). For example:\nYour firm’s procedure, Validation Program QA-035 Effective: 6\u002F11\u002F21, requires revalidation for previously validated process parameters, component changes, and major design changes; however, your firm did not revalidate your demineralization press when a major design change was made.\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding that during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating the potential shedding of (b)(4) particulates. Two corrective actions were implemented:\n(b)(4)\n(b)(4)\nYour firm updated TL-0091 for the Demineralization Press in design change order (DCO), DCO 6306 Released: 5\u002F24\u002F24, which changed the equipment design by (b)(4). Your firm determined that qualification or validation is not required, though the DCO describes the change category as Major. Your firm answered No to the question: Is there a change in the manufacturing equipment while maintaining the existing process? on your Form CPF-0302-001 Decision Tree, although your firm changed the equipment design by (b)(4). Your firm’s Director of Quality Systems and Assurance told the investigator that they considered the demineralization press to be a tool and not equipment.\nAdditionally, your firm determined that (b)(4) inspection was sufficient to identify potential (b)(4) contaminants and required training of your demineralization team to (b)(4) inspect the propellers, however your firm has not validated the (b)(4) inspection process for the propeller blades to demonstrate it is sufficient in identifying potential (b)(4) contaminants in your firm’s demineralized bone matrix (DBM). In an email from your firm’s manufacturing engineer, they note that (b)(4) particulates are (b)(4).\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address production and process related deficiencies identified in Observation 2. Actions include validating the (b)(4) inspection method with (b)(4) study, completing Installation Qualification for all (b)(4) demineralization assemblies, and establishing preventative maintenance and calibration programs. However, while your firm validated the inspection method and qualified equipment, there is no objective evidence that:\nAn evaluation of the existing process validation was conducted to determine if the changes to the demineralization assemblies could impact the applicability of the existing Operational and Performance Qualifications.\n(b)(4) particulate contamination is no longer occurring in production and that the (b)(4)\" clearance is sufficient to prevent all contact under all operating conditions\nTesting has been performed to confirm absence of (b)(4) particles in DBM\nFurthermore, the verification of effectiveness plan measures compliance to procedures and execution of preventative maintenance but does not include testing for (b)(4) particulates in finished product.\nAdditionally, it is not clear why the scope identified in CAPA-100520 for reviewing tooling changes is January 2022 to present, when the affected timeframe extends back to 2008.\n3. Failure to establish an adequate risk analysis, as required by 21 CFR 820.30(g). For example:\nYour firm’s procedure, CP-0305 Risk Management Rev. J1 Effective: 5\u002F27\u002F22, requires in Section 6.26.2 Perform Risk Reassessment (As Necessary), that if new or updated risk information is identified, it will be fed back into the risk management system and documented via update and approval of the appropriate risk management forms (such as the Hazard Analysis or FMEA).\nYour firm opened CAPA 157738 on 7\u002F27\u002F23 to address a finding, during the manufacturing process of demineralizing bone tissue, the propeller blade contacts the bottom of the demineralization vessel creating potential shedding of (b)(4) particulates. The CAPA identified the risk in PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II as (b)(4) for Supplier error leading to particulate contamination resulting in transient inflammation, which defined a severity of Moderate and a probability occurrence of Improbable, and the Risk Acceptability as Acceptable.\nYour firm identified the propeller blade was potentially shedding (b)(4) particulates during the demineralization process; however, your firm did not update PFMEA-001 for OrthoBlast II and PFMEA-002 DynaGraft II to identify this new risk factor. (b)(4) only addresses potential contaminants from your supplier resulting in transient inflammation and does not address the risk of contaminants during your firm’s manufacturing processes. Your firm did not identify the risk of (b)(4) contaminants and the potential impact to patient harm. Your firm’s risk management files were not updated after identifying this new risk, including identifying the severity of patient harm, as required by your procedure.\nAdditionally, your firm did not reevaluate the probability of occurrence for potential contaminants. (b)(4) Supplier error leading to particulate contamination resulting in transient inflammation defines a probability occurrence of Improbable. Your firm did not update the occurrence probability after identifying the new risk of potential (b)(4) contaminants.\nAccording to your firm’s Senior Manager, New Product Initiatives and Sustaining Engineering, since your firm implemented the demineralized process in 2008, (b)(4) particulates may have been present in your DBM, potentially impacting over (b)(4) devices.\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm opened CAPA-100520 to address risk management deficiencies identified in Observation 3. Although your firm acknowledges that risk assessment associated with CAPA 157738 and related PFMEAs and Hazard Analysis (HA-(b)(4)) required revision and initiated procedural changes, your response is still inadequate. Your firm’s actions included:\nUpdated PMFEAs ((b)(4)) to include (b)(4)\nUpdated Hazard Analysis HA-(b)(4) to (b)(4)\nConducted a retrospective Health Hazard Evaluation (HHE-(b)(4))\nHHE-(b)(4) concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that (b)(4) contamination occurred from 2008-2024, with over (b)(4) devices potentially affected, however no actual testing was performed to confirm the absence of (b)(4) in distributed product. The HHE is deficient in that:\nYour firm reviewed (b)(4) complaints and deemed (b)(4) clinically relevant for your probability calculation. There was no clear indication on which were not deemed clinically relevant and why. Your firm concluded that (b)(4) complaints related to (b)(4) contamination without adequately documenting an investigation showing how they ruled out (b)(4) contamination as a contributing factor.\nYour firm’s Probability Assessment disregards potential inflammation or foreign body reaction due to (b)(4) particles as typical post-surgical inflammation\nSeverity Assessment deemed Moderate, which firm has defined in your firm’s procedure, Risk Management Rev. J1 Effective: 5\u002F27\u002F22 and identified in the Severity Ratings Table in HHE-(b)(4) as a minor intervention (i.e. Medical intervention that may result in procedural delay, requiring removal and re-insertion of device resulting in additional patient discomfort or increased anesthesia requirements; Minor, transient, or self-limiting injury not requiring medical intervention; Cancellation of an elective medical procedure \u002F surgery). While complaint data included in HHE includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.\nBiocompatibility has not been adequately evaluated. Your firm states that (b)(4) is used in permanently implanted devices (stents, pledgets, endoprostheses), therefore, (b)(4) exposure is not expected to cause adverse effects. However, the cited devices use intact (b)(4) structures, not particulate contamination. Your firm provides no data demonstrating that they have:\no Characterized potential particle generation during normal use and wear.\no Conducted biocompatibility testing per ISO 10993 standards if particle release is expected.\no Assessed the clinical significance of any particle elution through risk analysis.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on October 6, 2025 through October 17, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723370” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","IsoTis OrthoBiologics, Inc.","isotis-orthobiologics-inc-723370-02242026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fisotis-orthobiologics-inc-723370-02242026","2026-10-26T08:09:01.474861+00:00","2026-03-24","723370","Peter P. Nalbach","2026-08-19T04:50:13.031+00:00","2026-02-24",{"id":225,"raw":226,"subject":231,"body_html":232,"body_text":233,"firm_name":234,"letter_id":235,"created_at":236,"fei_number":19,"letter_url":237,"updated_at":238,"action_type":22,"case_status":23,"posted_date":239,"marcs_cms_no":240,"product_type":241,"closeout_date":19,"issuing_office":230,"recipient_name":242,"body_fetched_at":243,"delivery_method":244,"recipient_title":19,"reference_number":19,"action_taken_date":245,"medical_device_id":19,"response_letter_date":19},21683,[227,228,229,230,231,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesbiodeseret-biologicals-inc-735464-10012026\">DesBio\u002FDeseret Biologicals, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jake Carter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DesBio\u002FDeseret Biologicals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>469 West Parkland Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:practitionersupport@desbio.com\"> practitionersupport@desbio.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 735464\u003C\u002Fp>\u003Cp>To Jake Carter:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fdesbio.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fdesbio.com\u002F in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “CHLA:10M” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003Cbr>On the product label:\u003C\u002Fp>\u003Cul>\u003Cli>“Chlamydia 10M”\u003C\u002Fli>\u003Cli>“Chlamydia trachomatis 10M . . . Burning Sensation During Urination, Testicular Tenderness or Pain, Vaginal Discharge, Painful Sexual Intercourse”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the webpage https:\u002F\u002Fdesbio.com\u002Fproduct\u002Fchlamydia-series-symptom-relief-series-kit-10m\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“chlamydia, series symptom relief”\u003C\u002Fli>\u003Cli>“CHLA:10M is for the temporary relief of symptoms related to Chlamydia infection. Male: burning sensation during urination and testicular tenderness or pain. Female: vaginal discharge, burning sensation during urination, and painful sexual intercourse.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“CHLA:10M” is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735464” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> We recognize that the “CHLA:10M” labeling describes the product as being “homeopathic.”\u003C\u002Fp>\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product contains Chlamydia trachomatis 10M which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\u003C\u002Fp>\u003Cp>Notwithstanding, even if your above listed product is considered “homeopathic drug product\" under this guidance, the product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJake Carter\n\nRecipient Title\n\nChief Executive Officer\n\nDesBio\u002FDeseret Biologicals, Inc.\n\n469 West Parkland Drive\n\nSandy, UT 84070\n\nUnited States\n\npractitionersupport@desbio.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 735464\nTo Jake Carter:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fdesbio.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fdesbio.com\u002F in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “CHLA:10M” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nOn the product label:\n“Chlamydia 10M”\n“Chlamydia trachomatis 10M . . . Burning Sensation During Urination, Testicular Tenderness or Pain, Vaginal Discharge, Painful Sexual Intercourse”\nOn the webpage https:\u002F\u002Fdesbio.com\u002Fproduct\u002Fchlamydia-series-symptom-relief-series-kit-10m\u002F:\n“chlamydia, series symptom relief”\n“CHLA:10M is for the temporary relief of symptoms related to Chlamydia infection. Male: burning sensation during urination and testicular tenderness or pain. Female: vaginal discharge, burning sensation during urination, and painful sexual intercourse.”\n“CHLA:10M” is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.1 Accordingly, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735464” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________________\n1 We recognize that the “CHLA:10M” labeling describes the product as being “homeopathic.”\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product contains Chlamydia trachomatis 10M which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\nNotwithstanding, even if your above listed product is considered “homeopathic drug product\" under this guidance, the product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","DesBio\u002FDeseret Biologicals, Inc.","desbiodeseret-biologicals-inc-735464-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesbiodeseret-biologicals-inc-735464-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","735464","Drugs Over-the-Counter Drugs","Jake Carter","2026-10-14T12:33:01.458+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":247,"raw":248,"subject":61,"body_html":251,"body_text":252,"firm_name":253,"letter_id":254,"created_at":18,"fei_number":19,"letter_url":255,"updated_at":256,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":257,"product_type":71,"closeout_date":19,"issuing_office":127,"recipient_name":258,"body_fetched_at":259,"delivery_method":161,"recipient_title":19,"reference_number":260,"action_taken_date":261,"medical_device_id":19,"response_letter_date":19},1077,[80,249,250,127,128,13,13,13],"\u003Ctime datetime=\"2024-12-30T05:00:00Z\">12\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024\">Evolutionary Biologics Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-681586\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Morrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evolutionary Biologics Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Penn Plaza West 34th Street Floor 9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@evolutionarybiologics.com\"> admin@evolutionarybiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 30, 2024\u003C\u002Fp>\u003Cp>Warning Letter #: CBER-24-681586\u003C\u002Fp>\u003Cp>Dear Mr. Morrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\u003C\u002Fp>\u003Cp>\u003Cu>EVO JEL™\u003C\u002Fu>\u003Cbr>• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\u003Cbr>• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\u003Cbr>• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder &amp; Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\u003C\u002Fp>\u003Cp>\u003Cu>EVO HYBRID™\u003C\u002Fu>\u003Cbr>• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\u003Cbr>• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\u003Cbr>&nbsp; &nbsp; • “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 &amp; 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\u003Cbr>&nbsp; &nbsp; • IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\u003Cbr>&nbsp; &nbsp; • B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\u003C\u002Fp>\u003Cp>\u003Cu>EXO RNA™\u003C\u002Fu>\u003Cbr>• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”&nbsp;&nbsp;\u003Cbr>• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\u003Cbr>&nbsp; &nbsp; • TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\u003C\u002Fp>\u003Cp>Based on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>In addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>Additionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>Therefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&amp;C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&amp;C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&amp;C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&amp;C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In addition, we have concerns with your products EXO RX, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong>, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\u003Cbr>• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\u003Cbr>• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\u003Cbr>• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\u003Cbr>• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”&nbsp;\u003Cbr>• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\u003Cbr>• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\u003C\u002Fp>\u003Cp>FDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong> products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\u003C\u002Fp>\u003Cp>Your response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>Melissa J. Mendoza\u003Cbr>Director, Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER-24-681586\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJim Morrison\n\nRecipient Title\n\nCEO\n\nEvolutionary Biologics Inc.\n\n14 Penn Plaza West 34th Street Floor 9\n\nNew York, NY 10122\n\nUnited States\n\nadmin@evolutionarybiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nDecember 30, 2024\nWarning Letter #: CBER-24-681586\nDear Mr. Morrison:\nThe United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\nEVO JEL™\n• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\n• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\n• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder & Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\nEVO HYBRID™\n• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\n• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\n• “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 & 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\n• IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\n• B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\nEXO RNA™\n• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”\n• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\n• TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\nYour product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\nBased on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\nFor example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\nIn addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nAdditionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.1\nIn addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\nTherefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\nIn addition, we have concerns with your products EXO RX, EXO ELIXIR™ and EXO PERIO™, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\n• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\n• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\n• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\n• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”\n• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\n• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\nFDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and EXO PERIO™ products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nYour response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\nMelissa J. Mendoza\nDirector, Office of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n______________________\n1 You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\n2 Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Evolutionary Biologics Inc.","evolutionary-biologics-inc-681586-12302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024","2026-10-26T08:08:37.862855+00:00","681586","Jim Morrison","2026-08-19T17:03:23.375+00:00","CBER-24-681586","2024-12-30",{"id":263,"raw":264,"subject":269,"body_html":270,"body_text":271,"firm_name":272,"letter_id":273,"created_at":110,"fei_number":19,"letter_url":274,"updated_at":275,"action_type":22,"case_status":23,"posted_date":276,"marcs_cms_no":277,"product_type":278,"closeout_date":19,"issuing_office":279,"recipient_name":280,"body_fetched_at":281,"delivery_method":74,"recipient_title":19,"reference_number":19,"action_taken_date":282,"medical_device_id":19,"response_letter_date":19},1614,[265,266,267,268,269,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-21T05:00:00Z\">12\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcurtis-jacquot-dba-pacific-biologic-co-664804-12212023\">Curtis Jacquot dba Pacific BioLogic Co.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","CGMP\u002FManufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Curtis D. Jacquot\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Curtis Jacquot dba Pacific BioLogic Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5514 Langford Ct\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Concord\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94521\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL 664804\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jacquot:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your manufacturing and distributing facility, located at 5514 Langford Ct, Concord, CA 94521, on June 1 through 29, 2023. The inspection revealed significant violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations Part 111 (21 CFR Part 111).\u003C\u002Fp>\n\n\u003Cp>In addition, FDA reviewed the labels for some of your products and the websites www.pacificbiologic.com and www.balanceandharmony.com in July 2023. The review of your labels and websites reveals that claims made for several of your products cause them to be drugs under sections 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Furthermore, several of your products are misbranded drugs under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] because they fail to bear adequate directions for their intended use(s).\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, on June 29, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response received via email dated July 14, 2023, which included your intended corrections to the observations of concern noted on the form FDA-483. However, the response was not adequate as further described in this letter. Your response targets completion of procedures to establish specifications by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, your response references forms or procedures that were not provided for review. We address your response more specifically below.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>We reviewed your websites www.pacificbiologic.com and www.balanceandharmony.com and we determined you take orders there for your products ArteClear Circulation 2, Headache Release, Natura-Mune – 2, Pain Release, and Attack 2. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>ArteClear Circulation 2\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fcardio-heart-health\u002Fcirculation\u002F\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“ArteClear: Circulation 2…cardio-protective ...formula, ischemic heart disease, post heart attack recovery…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Headache Release\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product name: “Headache Release”\u003Cbr>\nYour Information Panel: “Suggested Dosage ... Reduce the dosage and frequency as the condition improves.”\u003C\u002Fp>\n\n\u003Cp>On your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fsleep-stress-anxiety-support\u002Fheadache-release\u002F\u003Cbr>\n• “Non-aspirin”\u003Cbr>\n• “If you suffer from frequent headaches or migraines, you know how debilitating they can be. Fortunately, Pacific BioLogic’s Headache Release formula offers natural relief for headaches and migraines.”\u003Cbr>\n• “Dosage ... Best taken at the very onset. May be helpful to prevent onset of a migraine if taken at the onset of symptoms.”\u003Cbr>\n• “Corydalis”, an ingredient in the product, is listed under “[R]elieve pain and spasms”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Natura-Mune – 2\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fimmune-support\u002Fnatura-mune\u002F\u003Cbr>\n• “This formula is recommended to be included in a supplement support program when treating chronic deficiency-type diseases because of its superior balance and gentle strengthening qualities.”\u003Cbr>\n• “Categories: Cold &amp; Flu ... Oncology Support”\u003Cbr>\n• “More recently there have been extensive clinical studies that have identified a number of compounds in them [fungi and mushrooms, ingredients in Natura-Mune 2] that ... inhibit bacterial, viral, and tumor growth.\u003Cbr>\n• “Cat’s Claw and Pau d’Arcu[sic] [ingredients in Natura-Mune 2] are two well-known (and studied) South American herbs that have some similar properties. They have been used extensively to treat chronic illnesses and degenerative conditions.”\u003Cbr>\n• “Suggested Dosage ... Use higher dosage for more severe-immune compromised conditions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pain Release\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product name: “Pain Release”\u003Cbr>\nYour Information Panel: “Suggested Dosage: 1 – 4 capsules ... adjusting dosage according to level of pain and trauma”\u003C\u002Fp>\n\n\u003Cp>On your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fbone-joint-health\u002Fpain-release\u002F\u003Cbr>\n• “Regulates body pain and spasms due to trauma, sprains, or fractures. Best if taken during the critical first 24-48 hours after injury.”\u003Cbr>\n• “Pacific BioLogic’s Pain Release is a powerful supplement that provides natural support for those who suffer from chronic pain or inflammation. If you are looking for an effective solution to relieve pain and inflammation without resorting to over-the-counter painkillers or prescription medications, Pain Release may be just what you need.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Attack 2\u003C\u002Fstrong>\u003Cbr>\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fimmune-support\u002Fattack_2\u002F\u003Cbr>\n• [ingredients in the product Attack 2] “... Andrographis, Viola, Chrysanthemum Flower, Oregon Grape Root, and Licorice root. These herbs work well together to cover a very wide spectrum of bacterial and viral strains. Much research has been done on the benefits of Andrographis. Its properties include analgesic, anti-viral, anti-inflammatory, expectorant …”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the Warning Letter issued to you on April 17, 2014, and the items discussed with you in the Regulatory Meeting held on May 19, 2015.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)]), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products ArteClear Circulation 2, Natura-Mune – 2, and Attack 2 are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your products listed above fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your dietary supplement products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because the products have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111).\u003C\u002Fp>\n\n\u003Cp>The significant violations documented during the inspection include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish required specifications:\u003C\u002Fp>\n\n\u003Cp>• for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you failed to establish identity specifications for all components used in the manufacture of your dietary supplements, including ArteClear, Cholesterol, ArteClear Circulation 2, Pain Release, Grounded, and Attack 2.\u003Cbr>\n• for dietary supplement labels (label specifications) and for packaging that may come in contact with dietary supplements (packaging specifications), as required by 21 CFR 111.70(d). Specifically, when asked by the FDA investigator, you stated that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> deliver the blended\u002Fmilled ingredients to your contract manufacturer to encapsulate and bottle the capsules for you as per your verbal instructions.\u003Cbr>\n• product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e) for each dietary supplement that you manufacture. Specifically, when asked by the FDA investigator, you stated you do not have finished product specifications for your finished dietary supplement products, including ArteClear Cholesterol, ArteClear, Circulation 2, Pain Release, Grounded, and Attack 2.\u003C\u002Fp>\n\n\u003Cp>Your response to the FDA-483, received on July 14, 2023, is not adequate because in your response you state that your procedures for establishing identity specifications would be completed by December 2023 but you did not provide any copies of the procedures you mention in your response (such as QA-402 Product Specifications for Identity, Purity, Strength, and Composition, QA-403 Establish Product Specifications for Limits, QA-404 Component Specifications for Purity, Strength, and Composition and QA-405 which you say you intend will establish limits for contamination) or provide any written specifications for your components, packaging, labeling, or finished dietary supplement products.\u003C\u002Fp>\n\n\u003Cp>Once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75. Specifically, before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c). You must also make and keep certain records, including records of the specifications you establish, in accordance with 21 CFR 111.95. After establishing the above specifications, you must also collect representative samples of each unique lot of components, packaging and labels that you use to determine whether the components, packaging and labels meet established specifications, as required by 21 CFR 111.80(a).\u003C\u002Fp>\n\n\u003Cp>This is a repeat observation from the Warning Letter issued to you on April 17, 2014, and the items discussed with you in the Regulatory Meeting held on May 19, 2015.\u003C\u002Fp>\n\n\u003Cp>2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, when asked by the FDA investigator to provide specific MMRs, you said you did not have written MMRs for your finished products Headache Release, ArteClear Blood Pressure, and Natura-Mune 2.\u003C\u002Fp>\n\n\u003Cp>The written MMRs that you were able to provide failed to include all of the required information, in accordance with 21 CFR 111.210. Specifically, your MMRs for ArteClear Cholesterol ArteClear Circulation 2 and Grounded failed to include the following information:\u003Cbr>\n• An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\u003Cbr>\n• The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d]); A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\u003Cbr>\n• Written instructions, including the following [21 CFR 111.210(h)]:\u003Cbr>\no Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(1)];\u003Cbr>\no Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\u003Cbr>\no Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR.\u003Cbr>\n Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\u003Cbr>\n For manual operations, such specific actions must include [21 CFR 111.210(h)(3)(ii)]:\u003Cbr>\n One person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\u003Cbr>\n One person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)].\u003Cbr>\n• Corrective action plans for use when specifications are not met. [21 CFR 111.210(h)(5)]\u003C\u002Fp>\n\n\u003Cp>Your response to the FDA-483, received on July 14, 2023, states that you did not fill out the document correctly and that the requirements for your MMRs can be found in document QA-500. We are unable to determine the adequacy of your corrective actions because you did not provide a copy of document QA-500. You also failed to provide MMRs for your finished products Headache Release, ArteClear Blood Pressure, and Natura-Mune 2 and you failed to provide updated MMRs for your finished products ArteClear Cholesterol, ArteClear Circulation 2, and Grounded.\u003C\u002Fp>\n\n\u003Cp>3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplements, as required by 21 CFR 111.255(a). Specifically, you did not prepare a BPR for any of your finished products, including but not limited to Grounded, (Lots 204049, 204023, 204024), Headache Release (Lot 204043), ArteClear Blood Pressure (Lot 204032), Natura-Mune 2 (Lot 204038), ArteClear Cholesterol (Lot 204041), and ArteClear Circulation 2 (Lot 203986), as well as for the products Pain Release, Grounded, and Attack 2.\u003C\u002Fp>\n\n\u003Cp>4. You failed to review all product complaints to determine whether any product complaints involved a possible failure of a dietary supplement to meet any of its specifications, or any other requirements of part 111, including those specifications and other requirements that, if not met, may result in a risk of illness or injury, as required under 21 CFR 111.560(a)(1). You also failed to make and keep a written record of every product complaint related to good manufacturing practice, as required by 21 CFR 111.570(b)(2). Specifically, during the inspection you stated that you remembered you had your herbal and dietary supplement products returned but that you could not recall when or what herbal and dietary supplement products had been returned.\u003C\u002Fp>\n\n\u003Cp>Your response to the FDA-483, received on July 14, 2023, states that you have located your file for the Complaint Report Log (QA-301 L), Return Authorization Form, Consumer Complaint Medical Question Form, and Consumer Complaint &amp; Adverse Event Reporting (AER) form; however, we are unable to evaluate the adequacy of your corrective actions because you did not provide the referenced documents for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to make and keep records of any material review and disposition decision on a returned dietary supplement, as required by 21 CFR 111.535(b)(2). Specifically, during the inspection you stated that you remembered you had your herbal and dietary supplement products returned but you could not recall when or what herbal and dietary supplements were returned.\u003C\u002Fp>\n\n\u003Cp>In your response to the FDA-483, received on July 14, 2023, you referenced a procedure QA-301, “Returned Merchandise.” You did not provide a copy of this procedure. You did not provide evidence of any material review and deposition of returned dietary supplements.\u003C\u002Fp>\n\n\u003Cp>6. You failed to collect and hold reserve samples of each lot of packaged and labeled dietary supplements that you distribute, as required by 21 CFR 111.83(a). Specifically, you told an FDA investigator that you do not currently collect and hold reserve samples of the products that you distribute. You stated that you have not collected reserve samples since 2018, and that you no longer collect reserve samples due to a lack of space within your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response to the FDA-483, received on July 14, 2023, you referenced a procedure QA-401, “Collecting and Reserve Samples.” You did not provide a copy of this procedure. You also stated that you will figure out a way to record and label the storage container used for this purpose, but you provided no evidence of your corrective action plan, such as a reserve sample log.\u003C\u002Fp>\n\n\u003Cp>7. Your quality control personnel failed to ensure that your manufacturing, packaging, labeling, and holding operations ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.105. Specifically, the components listed in your master manufacturing records do not match the components listed on the dietary supplement product label. For example:\u003Cbr>\n• The MMR for your product Grounded lot #204023 and lot #204024 list the component Inositol NF\u002FFCC; however, Inositol is not listed on the Grounded product label.\u003C\u002Fp>\n\n\u003Cp>We note that the MMR for your product Attack 2 lot #204009 lists the component White Mulberry bark; however, White Mulberry bark is circled by hand, and Andrographis is handwritten beside it. Therefore, it is unclear whether the MMR lists the component White Mulberry bark and Andrographis as being added during manufacturing, or whether the MMR lists Andrographis as being added twice during manufacturing, once on its own, and once to replace the White Mulberry bark component. The product label lists both White Mulberry bark and Andrographis as dietary ingredients in the Attack 2 product.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed product labels collected during the inspection and have determined the Pain Release, Headache Release, ArteClear Circulation 2, and Grounded dietary supplements you manufacture and distribute are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your products Pain Release, and Headache Release, ArteClear Circulation 2, and Grounded are misbranded within the meaning of section 403(i)(2) of the Act in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h)(2). For example,\u003C\u002Fp>\n\n\u003Cp>Pain Release\u003Cbr>\n• The product label declares “Boswellia resin”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Frankincense.”\u003Cbr>\n• The product label declares “Notoginseng”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Tienchi Ginseng.”\u003Cbr>\n• The standardized common name for Drynaria fortune given in the reference Herbs of Commerce is “drynaria.”\u003Cbr>\n• The product label declares “Corydalis”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Corydalis yanhusuo.”\u003Cbr>\n• Your product labels declare “capsules of plant origin”, but this is not a common or usual name for an ingredient.\u003C\u002Fp>\n\n\u003Cp>Headache Release\u003Cbr>\n• The product label declares “Citrus viride”, but this is not the common of usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Tangerine.”\u003Cbr>\n• Although the Latin binomial name is declared, it must be placed in parentheses following the standardized common name “Wood Betony.”\u003Cbr>\n• The standardized common name for Chrysanthemum x morifolium given in the reference Herbs of Commerce, is “chrysanthemum.”\u003Cbr>\n• The product label declares “Pueraria spp.”, but this is not the common of usual name of a dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce for the specific species, and in the absence of a standardized common name, the Latin binomial name.\u003Cbr>\n• The standardized common name for Gastrodia elata given in the reference Herbs of Commerce, is “Gastrodia.”\u003C\u002Fp>\n\n\u003Cp>ArteClear Circulation 2\u003Cbr>\n• The product declares “BioPerine ® (Trademark of Sabinsa Corp.)”, which is a trademarked term and not the common or usual name for the ingredient.\u003C\u002Fp>\n\n\u003Cp>Grounded\u003Cbr>\n• “MSM” is not the common or usual name for the ingredient Methylsulfonylmethane.\u003C\u002Fp>\n\n\u003Cp>2. Your products Pain Release, Headache Release, and ArteClear Circulation 2 are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)], in that the labels fail to identity the part of the plant or fail to express the name in English, as required by 21 CFR 101.4(h)(1). For example,\u003C\u002Fp>\n\n\u003Cp>Pain Release:\u003Cbr>\n• The dietary ingredient “Notoginseng Radix” uses the Latin term “radix” for the plant part. The name must be expressed in English.\u003Cbr>\n• The label does not list the plant part for myrrh, sappan wood, and Schefflera arboricola. If the whole or entire plant is used, that information must be listed.\u003C\u002Fp>\n\n\u003Cp>Headache Release:\u003Cbr>\n• The label does not list the plant part for Stachys officinalis, Chrysanthemum morifolium, and Uncaria rhynchopylfa. If the entire or whole plant is used, that information must be declared.\u003C\u002Fp>\n\n\u003Cp>ArteClear Circulation 2\u003Cbr>\n• The label does not list the plant part for Cayenne pepper.\u003C\u002Fp>\n\n\u003Cp>3. Your products “Pain Release”, “Headache Release”, “ArteClear Circulation 2”, “Natura-Mune 2”, “Attack 2”, “ArteClear Cholesterol”, “ArteClear Blood Pressure” and “Grounded” are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343 (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products is not in accordance with 21 CFR 101.36 and 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>• The title, “Supplement Facts”, should be set to full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The nutrition information, i.e., the Supplement Facts label, must include the required title, subheadings, usage of heavy and light bars, and hairlines within the box [21 CFR 101.36(e)].\u003Cbr>\n• The dietary ingredients comprising the “Proprietary Blend” fail to have hairline rules centered between the lines of text such that the hairline rules separate the dietary ingredients above from the dietary ingredients below, in accordance with 21 CFR 101.36(c)(2) and (e)(5).\u003Cbr>\n• Your product labels which do not declare a proprietary blend must bear the quantitative amounts by weight of each other dietary ingredient under the heading “Amount Per Serving”, in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n• Your product labels present the nutrition information as per capsule and not on a per serving basis, which is not in accordance with 21 CFR 101.9(b).\u003Cbr>\n• Your product “Headache Release” incorrectly declares the servings per container [21 CFR 101.9(b)(8)].\u003Cbr>\n• Your product labels “Pain Release” and “ArteClear Cholesterol” do not declare the components of the “Proprietary Blend” in descending order of predominance by weight, as indicated by the Master Manufacturing Record (MMR) [21 CFR 101.36(c)(2)].\u003C\u002Fp>\n\n\u003Cp>Grounded\u003C\u002Fp>\n\n\u003Cp>• The source of the dietary ingredients, niacin, vitamin B6, magnesium, and zinc must be declared in accordance with 21 CFR 101.36(d).\u003Cbr>\n• The quantitative amount by weight per serving of the proprietary blend does not use metric measures in appropriate units (i.e., 3000 units must be declared in the next higher set of units, e.g., 6000 mg must be expressed as 6 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A). Furthermore, the dietary ingredients comprising the proprietary blend are not indented under the title “Proprietary Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• Potassium must not be listed within the Supplement Facts label because the serving contains less than 2% of the Recommended Daily Intake (RDI), which is considered zero. Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in section 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\u003C\u002Fp>\n\n\u003Cp>4. Your product “Circulation 2” is misbranded within the meaning of section 403(r)(6) in that the product makes structure\u002Ffunction claims but fails to bear the required dietary supplement disclaimer, in accordance with 21 CFR 101.93(b)-(e).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments:\u003C\u002Fp>\n\n\u003Cp>Regarding your labels\u003Cbr>\n• For the product “Grounded” Lithium orotate is misspelled.\u003Cbr>\n• For the product “Pain Release”, the dietary ingredient sappanwood should be one word.\u003Cbr>\n• For the product “ArteClear Circulation 2”, the standardized common name for Panax ginseng given in the reference Herbs of Commerce is “Oriental ginseng.” However, we would not object to use of “Asian ginseng” as given in the 2nd edition (2000) of Herbs of Commerce.\u003C\u002Fp>\n\n\u003Cp>Regarding your response\u003C\u002Fp>\n\n\u003Cp>In your response to the FDA-483, received on July 14, 2023, you outline your plan to provide all new and updated SOPs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We note that this does not constitute a reasonable timeframe given many of these citations are repeat citations from past inspections, and given you received a Warning letter in 2014 and participated in a Regulatory Meeting in 2015 about many of these citations. Please provide an updated timeline for the completion of your new and updated SOPs.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Pkwy\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number \u003Cstrong>664804\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Curtis D. Jacquot\n\nRecipient Title\n\nPresident and Owner\n\nCurtis Jacquot dba Pacific BioLogic Co.\n\n5514 Langford Ct\n\nConcord, CA 94521\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nWL 664804\n\nDear Mr. Jacquot:\n\nThe United States Food and Drug Administration (FDA) inspected your manufacturing and distributing facility, located at 5514 Langford Ct, Concord, CA 94521, on June 1 through 29, 2023. The inspection revealed significant violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, Title 21, Code of Federal Regulations Part 111 (21 CFR Part 111).\n\nIn addition, FDA reviewed the labels for some of your products and the websites www.pacificbiologic.com and www.balanceandharmony.com in July 2023. The review of your labels and websites reveals that claims made for several of your products cause them to be drugs under sections 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. §§ 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. Furthermore, several of your products are misbranded drugs under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] because they fail to bear adequate directions for their intended use(s).\n\nAt the close of the inspection, on June 29, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response received via email dated July 14, 2023, which included your intended corrections to the observations of concern noted on the form FDA-483. However, the response was not adequate as further described in this letter. Your response targets completion of procedures to establish specifications by (b)(4). Additionally, your response references forms or procedures that were not provided for review. We address your response more specifically below.\n\nUnapproved New Drugs\n\nWe reviewed your websites www.pacificbiologic.com and www.balanceandharmony.com and we determined you take orders there for your products ArteClear Circulation 2, Headache Release, Natura-Mune – 2, Pain Release, and Attack 2. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nArteClear Circulation 2\n\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fcardio-heart-health\u002Fcirculation\u002F\n\n“ArteClear: Circulation 2…cardio-protective ...formula, ischemic heart disease, post heart attack recovery…”\n\nHeadache Release\n\nYour product name: “Headache Release”\n\nYour Information Panel: “Suggested Dosage ... Reduce the dosage and frequency as the condition improves.”\n\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fsleep-stress-anxiety-support\u002Fheadache-release\u002F\n\n• “Non-aspirin”\n\n• “If you suffer from frequent headaches or migraines, you know how debilitating they can be. Fortunately, Pacific BioLogic’s Headache Release formula offers natural relief for headaches and migraines.”\n\n• “Dosage ... Best taken at the very onset. May be helpful to prevent onset of a migraine if taken at the onset of symptoms.”\n\n• “Corydalis”, an ingredient in the product, is listed under “[R]elieve pain and spasms”\n\nNatura-Mune – 2\n\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fimmune-support\u002Fnatura-mune\u002F\n\n• “This formula is recommended to be included in a supplement support program when treating chronic deficiency-type diseases because of its superior balance and gentle strengthening qualities.”\n\n• “Categories: Cold & Flu ... Oncology Support”\n\n• “More recently there have been extensive clinical studies that have identified a number of compounds in them [fungi and mushrooms, ingredients in Natura-Mune 2] that ... inhibit bacterial, viral, and tumor growth.\n\n• “Cat’s Claw and Pau d’Arcu[sic] [ingredients in Natura-Mune 2] are two well-known (and studied) South American herbs that have some similar properties. They have been used extensively to treat chronic illnesses and degenerative conditions.”\n\n• “Suggested Dosage ... Use higher dosage for more severe-immune compromised conditions.\n\nPain Release\n\nYour product name: “Pain Release”\n\nYour Information Panel: “Suggested Dosage: 1 – 4 capsules ... adjusting dosage according to level of pain and trauma”\n\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fbone-joint-health\u002Fpain-release\u002F\n\n• “Regulates body pain and spasms due to trauma, sprains, or fractures. Best if taken during the critical first 24-48 hours after injury.”\n\n• “Pacific BioLogic’s Pain Release is a powerful supplement that provides natural support for those who suffer from chronic pain or inflammation. If you are looking for an effective solution to relieve pain and inflammation without resorting to over-the-counter painkillers or prescription medications, Pain Release may be just what you need.”\n\nAttack 2\n\nOn your webpage: https:\u002F\u002Fpacificbiologic.com\u002Fshop\u002Fimmune-support\u002Fattack_2\u002F\n\n• [ingredients in the product Attack 2] “... Andrographis, Viola, Chrysanthemum Flower, Oregon Grape Root, and Licorice root. These herbs work well together to cover a very wide spectrum of bacterial and viral strains. Much research has been done on the benefits of Andrographis. Its properties include analgesic, anti-viral, anti-inflammatory, expectorant …”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nThis is a repeat observation from the Warning Letter issued to you on April 17, 2014, and the items discussed with you in the Regulatory Meeting held on May 19, 2015.\n\nMisbranded Drugs\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)]), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products ArteClear Circulation 2, Natura-Mune – 2, and Attack 2 are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your products listed above fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nAdulterated Dietary Supplements\n\nYour dietary supplement products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] because the products have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111).\n\nThe significant violations documented during the inspection include, but are not limited to, the following:\n\n1. You failed to establish required specifications:\n\n• for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b). Specifically, you failed to establish identity specifications for all components used in the manufacture of your dietary supplements, including ArteClear, Cholesterol, ArteClear Circulation 2, Pain Release, Grounded, and Attack 2.\n\n• for dietary supplement labels (label specifications) and for packaging that may come in contact with dietary supplements (packaging specifications), as required by 21 CFR 111.70(d). Specifically, when asked by the FDA investigator, you stated that you (b)(4) deliver the blended\u002Fmilled ingredients to your contract manufacturer to encapsulate and bottle the capsules for you as per your verbal instructions.\n\n• product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e) for each dietary supplement that you manufacture. Specifically, when asked by the FDA investigator, you stated you do not have finished product specifications for your finished dietary supplement products, including ArteClear Cholesterol, ArteClear, Circulation 2, Pain Release, Grounded, and Attack 2.\n\nYour response to the FDA-483, received on July 14, 2023, is not adequate because in your response you state that your procedures for establishing identity specifications would be completed by December 2023 but you did not provide any copies of the procedures you mention in your response (such as QA-402 Product Specifications for Identity, Purity, Strength, and Composition, QA-403 Establish Product Specifications for Limits, QA-404 Component Specifications for Purity, Strength, and Composition and QA-405 which you say you intend will establish limits for contamination) or provide any written specifications for your components, packaging, labeling, or finished dietary supplement products.\n\nOnce you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75. Specifically, before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, for a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c). You must also make and keep certain records, including records of the specifications you establish, in accordance with 21 CFR 111.95. After establishing the above specifications, you must also collect representative samples of each unique lot of components, packaging and labels that you use to determine whether the components, packaging and labels meet established specifications, as required by 21 CFR 111.80(a).\n\nThis is a repeat observation from the Warning Letter issued to you on April 17, 2014, and the items discussed with you in the Regulatory Meeting held on May 19, 2015.\n\n2. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, when asked by the FDA investigator to provide specific MMRs, you said you did not have written MMRs for your finished products Headache Release, ArteClear Blood Pressure, and Natura-Mune 2.\n\nThe written MMRs that you were able to provide failed to include all of the required information, in accordance with 21 CFR 111.210. Specifically, your MMRs for ArteClear Cholesterol ArteClear Circulation 2 and Grounded failed to include the following information:\n\n• An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\n\n• The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d]); A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\n\n• Written instructions, including the following [21 CFR 111.210(h)]:\n\no Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(1)];\n\no Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\n\no Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR.\n\n Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\n\n For manual operations, such specific actions must include [21 CFR 111.210(h)(3)(ii)]:\n\n One person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\n\n One person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)].\n\n• Corrective action plans for use when specifications are not met. [21 CFR 111.210(h)(5)]\n\nYour response to the FDA-483, received on July 14, 2023, states that you did not fill out the document correctly and that the requirements for your MMRs can be found in document QA-500. We are unable to determine the adequacy of your corrective actions because you did not provide a copy of document QA-500. You also failed to provide MMRs for your finished products Headache Release, ArteClear Blood Pressure, and Natura-Mune 2 and you failed to provide updated MMRs for your finished products ArteClear Cholesterol, ArteClear Circulation 2, and Grounded.\n\n3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplements, as required by 21 CFR 111.255(a). Specifically, you did not prepare a BPR for any of your finished products, including but not limited to Grounded, (Lots 204049, 204023, 204024), Headache Release (Lot 204043), ArteClear Blood Pressure (Lot 204032), Natura-Mune 2 (Lot 204038), ArteClear Cholesterol (Lot 204041), and ArteClear Circulation 2 (Lot 203986), as well as for the products Pain Release, Grounded, and Attack 2.\n\n4. You failed to review all product complaints to determine whether any product complaints involved a possible failure of a dietary supplement to meet any of its specifications, or any other requirements of part 111, including those specifications and other requirements that, if not met, may result in a risk of illness or injury, as required under 21 CFR 111.560(a)(1). You also failed to make and keep a written record of every product complaint related to good manufacturing practice, as required by 21 CFR 111.570(b)(2). Specifically, during the inspection you stated that you remembered you had your herbal and dietary supplement products returned but that you could not recall when or what herbal and dietary supplement products had been returned.\n\nYour response to the FDA-483, received on July 14, 2023, states that you have located your file for the Complaint Report Log (QA-301 L), Return Authorization Form, Consumer Complaint Medical Question Form, and Consumer Complaint & Adverse Event Reporting (AER) form; however, we are unable to evaluate the adequacy of your corrective actions because you did not provide the referenced documents for review.\n\n5. You failed to make and keep records of any material review and disposition decision on a returned dietary supplement, as required by 21 CFR 111.535(b)(2). Specifically, during the inspection you stated that you remembered you had your herbal and dietary supplement products returned but you could not recall when or what herbal and dietary supplements were returned.\n\nIn your response to the FDA-483, received on July 14, 2023, you referenced a procedure QA-301, “Returned Merchandise.” You did not provide a copy of this procedure. You did not provide evidence of any material review and deposition of returned dietary supplements.\n\n6. You failed to collect and hold reserve samples of each lot of packaged and labeled dietary supplements that you distribute, as required by 21 CFR 111.83(a). Specifically, you told an FDA investigator that you do not currently collect and hold reserve samples of the products that you distribute. You stated that you have not collected reserve samples since 2018, and that you no longer collect reserve samples due to a lack of space within your (b)(4).\n\nIn your response to the FDA-483, received on July 14, 2023, you referenced a procedure QA-401, “Collecting and Reserve Samples.” You did not provide a copy of this procedure. You also stated that you will figure out a way to record and label the storage container used for this purpose, but you provided no evidence of your corrective action plan, such as a reserve sample log.\n\n7. Your quality control personnel failed to ensure that your manufacturing, packaging, labeling, and holding operations ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.105. Specifically, the components listed in your master manufacturing records do not match the components listed on the dietary supplement product label. For example:\n\n• The MMR for your product Grounded lot #204023 and lot #204024 list the component Inositol NF\u002FFCC; however, Inositol is not listed on the Grounded product label.\n\nWe note that the MMR for your product Attack 2 lot #204009 lists the component White Mulberry bark; however, White Mulberry bark is circled by hand, and Andrographis is handwritten beside it. Therefore, it is unclear whether the MMR lists the component White Mulberry bark and Andrographis as being added during manufacturing, or whether the MMR lists Andrographis as being added twice during manufacturing, once on its own, and once to replace the White Mulberry bark component. The product label lists both White Mulberry bark and Andrographis as dietary ingredients in the Attack 2 product.\n\nMisbranded Dietary Supplements\n\nIn addition, we reviewed product labels collected during the inspection and have determined the Pain Release, Headache Release, ArteClear Circulation 2, and Grounded dietary supplements you manufacture and distribute are misbranded under section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your products Pain Release, and Headache Release, ArteClear Circulation 2, and Grounded are misbranded within the meaning of section 403(i)(2) of the Act in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h)(2). For example,\n\nPain Release\n\n• The product label declares “Boswellia resin”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Frankincense.”\n\n• The product label declares “Notoginseng”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Tienchi Ginseng.”\n\n• The standardized common name for Drynaria fortune given in the reference Herbs of Commerce is “drynaria.”\n\n• The product label declares “Corydalis”, but this is not the common or usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Corydalis yanhusuo.”\n\n• Your product labels declare “capsules of plant origin”, but this is not a common or usual name for an ingredient.\n\nHeadache Release\n\n• The product label declares “Citrus viride”, but this is not the common of usual name of the dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce, “Tangerine.”\n\n• Although the Latin binomial name is declared, it must be placed in parentheses following the standardized common name “Wood Betony.”\n\n• The standardized common name for Chrysanthemum x morifolium given in the reference Herbs of Commerce, is “chrysanthemum.”\n\n• The product label declares “Pueraria spp.”, but this is not the common of usual name of a dietary ingredient. The label must list the standardized common name given in the reference Herbs of Commerce for the specific species, and in the absence of a standardized common name, the Latin binomial name.\n\n• The standardized common name for Gastrodia elata given in the reference Herbs of Commerce, is “Gastrodia.”\n\nArteClear Circulation 2\n\n• The product declares “BioPerine ® (Trademark of Sabinsa Corp.)”, which is a trademarked term and not the common or usual name for the ingredient.\n\nGrounded\n\n• “MSM” is not the common or usual name for the ingredient Methylsulfonylmethane.\n\n2. Your products Pain Release, Headache Release, and ArteClear Circulation 2 are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)], in that the labels fail to identity the part of the plant or fail to express the name in English, as required by 21 CFR 101.4(h)(1). For example,\n\nPain Release:\n\n• The dietary ingredient “Notoginseng Radix” uses the Latin term “radix” for the plant part. The name must be expressed in English.\n\n• The label does not list the plant part for myrrh, sappan wood, and Schefflera arboricola. If the whole or entire plant is used, that information must be listed.\n\nHeadache Release:\n\n• The label does not list the plant part for Stachys officinalis, Chrysanthemum morifolium, and Uncaria rhynchopylfa. If the entire or whole plant is used, that information must be declared.\n\nArteClear Circulation 2\n\n• The label does not list the plant part for Cayenne pepper.\n\n3. Your products “Pain Release”, “Headache Release”, “ArteClear Circulation 2”, “Natura-Mune 2”, “Attack 2”, “ArteClear Cholesterol”, “ArteClear Blood Pressure” and “Grounded” are misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343 (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products is not in accordance with 21 CFR 101.36 and 101.9. For example:\n\n• The title, “Supplement Facts”, should be set to full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The nutrition information, i.e., the Supplement Facts label, must include the required title, subheadings, usage of heavy and light bars, and hairlines within the box [21 CFR 101.36(e)].\n\n• The dietary ingredients comprising the “Proprietary Blend” fail to have hairline rules centered between the lines of text such that the hairline rules separate the dietary ingredients above from the dietary ingredients below, in accordance with 21 CFR 101.36(c)(2) and (e)(5).\n\n• Your product labels which do not declare a proprietary blend must bear the quantitative amounts by weight of each other dietary ingredient under the heading “Amount Per Serving”, in accordance with 21 CFR 101.36(b)(3).\n\n• Your product labels present the nutrition information as per capsule and not on a per serving basis, which is not in accordance with 21 CFR 101.9(b).\n\n• Your product “Headache Release” incorrectly declares the servings per container [21 CFR 101.9(b)(8)].\n\n• Your product labels “Pain Release” and “ArteClear Cholesterol” do not declare the components of the “Proprietary Blend” in descending order of predominance by weight, as indicated by the Master Manufacturing Record (MMR) [21 CFR 101.36(c)(2)].\n\nGrounded\n\n• The source of the dietary ingredients, niacin, vitamin B6, magnesium, and zinc must be declared in accordance with 21 CFR 101.36(d).\n\n• The quantitative amount by weight per serving of the proprietary blend does not use metric measures in appropriate units (i.e., 3000 units must be declared in the next higher set of units, e.g., 6000 mg must be expressed as 6 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A). Furthermore, the dietary ingredients comprising the proprietary blend are not indented under the title “Proprietary Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• Potassium must not be listed within the Supplement Facts label because the serving contains less than 2% of the Recommended Daily Intake (RDI), which is considered zero. Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in section 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\n\n4. Your product “Circulation 2” is misbranded within the meaning of section 403(r)(6) in that the product makes structure\u002Ffunction claims but fails to bear the required dietary supplement disclaimer, in accordance with 21 CFR 101.93(b)-(e).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comments:\n\nRegarding your labels\n\n• For the product “Grounded” Lithium orotate is misspelled.\n\n• For the product “Pain Release”, the dietary ingredient sappanwood should be one word.\n\n• For the product “ArteClear Circulation 2”, the standardized common name for Panax ginseng given in the reference Herbs of Commerce is “Oriental ginseng.” However, we would not object to use of “Asian ginseng” as given in the 2nd edition (2000) of Herbs of Commerce.\n\nRegarding your response\n\nIn your response to the FDA-483, received on July 14, 2023, you outline your plan to provide all new and updated SOPs by (b)(4). We note that this does not constitute a reasonable timeframe given many of these citations are repeat citations from past inspections, and given you received a Warning letter in 2014 and participated in a Regulatory Meeting in 2015 about many of these citations. Please provide an updated timeline for the completion of your new and updated SOPs.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Pkwy\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number 664804 when replying.\n\nIf you would prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification Number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at Elodie.Tong-Lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5","Curtis Jacquot dba Pacific BioLogic Co.","curtis-jacquot-dba-pacific-biologic-co-664804-12212023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcurtis-jacquot-dba-pacific-biologic-co-664804-12212023","2026-10-26T08:08:20.003407+00:00","2024-02-13","664804","Dietary Supplements","Division of Human and Animal Food Operations West V","Mr. Curtis D. Jacquot","2026-08-20T00:18:05.849+00:00","2023-12-21",{"id":284,"raw":285,"subject":289,"body_html":290,"body_text":291,"firm_name":292,"letter_id":293,"created_at":216,"fei_number":19,"letter_url":294,"updated_at":295,"action_type":22,"case_status":23,"posted_date":296,"marcs_cms_no":297,"product_type":202,"closeout_date":19,"issuing_office":230,"recipient_name":298,"body_fetched_at":299,"delivery_method":300,"recipient_title":19,"reference_number":301,"action_taken_date":302,"medical_device_id":19,"response_letter_date":19},248,[286,287,288,230,289,13,13,13],"\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-16T04:00:00Z\">03\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026\">Microbiological Testing &amp; Consulting, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-53\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lauren Szarzynski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Microbiological Testing &amp; Consulting, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5661 W. 120th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lauren@mtcresearch.com\"> lauren@mtcresearch.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-53\u003C\u002Fp>\u003Cp>March 16, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Szarzynski:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing &amp; Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Adequate Documentation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\u003C\u002Fp>\u003Cul>\u003Cli>equipment number\u003C\u002Fli>\u003Cli>sample size\u003C\u002Fli>\u003Cli>media batch number\u003C\u002Fli>\u003Cli>sample dilutions\u003C\u002Fli>\u003Cli>incubation temperatures\u003C\u002Fli>\u003Cli>name\u002Fsignature of performing analyst\u003C\u002Fli>\u003C\u002Ful>\u003Cp>According to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\u003C\u002Fp>\u003Cp>Additionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Laboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\u003C\u002Fp>\u003Cp>Complete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Appropriate Media Qualification\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\u003C\u002Fp>\u003Cp>As noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\u003C\u002Fp>\u003Cp>Furthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\u003C\u002Fp>\u003Cp>In your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\u003C\u002Fp>\u003Cp>Be reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\u003C\u002Fp>\u003Cp>\u003Cem>Training Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\u003C\u002Fp>\u003Cp>In your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\u003Cbr>o Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\u003Cbr>o For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\u003Cbr>o Revised OOL\u002FOOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>A description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\u003C\u002Fli>\u003Cli>Documentation of training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003Cbr>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities of Contract Testing Lab\u003C\u002Fstrong>\u003Cbr>FDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-53\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Lauren Szarzynski\n\nRecipient Title\n\nOwner\n\nMicrobiological Testing & Consulting, LLC\n\n5661 W. 120th Street\n\nAlsip, IL 60803\n\nUnited States\n\nlauren@mtcresearch.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-53\nMarch 16, 2026\nDear Ms. Szarzynski:\nThe United States Food and Drug Administration (FDA) inspected your contract testing laboratory, Microbiological Testing & Consulting, LLC, FEI 3003875820, at 5661 W. 120th Street, Alsip, from September 8 to 16, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, the drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.160(b) and 21 CFR 211.165(b)).\nYour firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for your customers. You failed to conduct appropriate testing to ensure that the results your firm provided to customers were accurate and scientifically sound.\nLack of Adequate Documentation\nYour firm lacks significant CGMP documentation for your microbiological testing. For example, you routinely failed to document specific attributes of each test such as:\nequipment number\nsample size\nmedia batch number\nsample dilutions\nincubation temperatures\nname\u002Fsignature of performing analyst\nAccording to your personnel, your firm also lacked adequate equipment logs to track usage and maintenance.\nYour response is inadequate. You commit to performing a comprehensive review of your testing operations and records. Based on the outcome of the review, your firm plans to update the affected data and test forms. You did not provide specific details on the records, equipment, and data that will be evaluated, nor did you commit to conducting a full retrospective review of test results provided to your customers.\nAdditionally, you indicate that going forward you will meet standards for laboratory studies. Please note that appropriate regulatory requirements for laboratories conducting testing for drug product manufacturers are 21 CFR parts 210 and 211 and Section 501(a)(2)(B) of the FD&C Act.\nLaboratory investigations cannot be performed when systems, procedures, and documentation are deficient.\nComplete and accurate records are necessary to ensure that test methods are consistently followed and reproducible. Additionally, complete test records are necessary to reliably conduct record reviews and adequately investigate deviations and drug product failures.\nLack of Appropriate Media Qualification\nYou lack adequate controls to ensure the reliability of your microbiological testing results. For example, the media used to test your customers drug products was inadequately qualified. You lacked screening for inhibitory properties of your incoming lots of (b)(4).\nIn your response, you commit to reviewing your tests and methods to identify gaps and implement the appropriate remediation.\nYour response is inadequate because you did not commit to pausing testing until assessments are complete, nor did you implement any interim corrective actions. Furthermore, your firm did not provide a plan to re-assess results that have been communicated to customers.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, test results, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA retrospective risk assessment of gaps found in your growth media qualification and suitability testing practices over the past three years. Describe how these gaps will be remediated to ensure reliable microbial enumeration and appropriate identification of objectionable microorganisms.\nA complete assessment of documentation systems used throughout your laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm lacks appropriate systems and procedures for quality oversight of laboratory testing, documentation, and investigations.\nAs noted in the prior charge, your quality unit did not have adequate oversight of documentation, media qualification, and other critical microbiology laboratory programs. In addition, you lacked adequate systems for investigations and ensuring analyst competencies.\nFurthermore, your management stated that in the past two years your firm conducted only one product out-of-specification (OOS) investigation and one water out-of-limit (OOL) for total aerobic microbial count (TAMC) investigation. These two investigations were the only ones available for our investigator to review. However, records collected during an FDA inspection of one of your customers (b)(4), indicated that your firm reported several OOL for TAMC and objectionable microorganism results within the past two years. It appears that your firm did not make all requested OOS\u002FOOL test data available during the inspection.\nIn your response, you commit to implement a multiphase OOS investigation methodology. Your response is inadequate. You did not commit to assessing previous OOS results to ensure the investigations were adequate.\nBe reminded that it is your responsibility to ensure all data and information provided are accurate, complete, and readily available for inspection. As a contract laboratory, you must comply with the CGMP regulations that apply to operations you perform, including, but not limited to, those that address the operations of your quality control unit, laboratory, investigation system, and documentation system.\nTraining Program\nYour training program is inadequate. CGMP training is not regularly performed at your firm as required by your established procedure. During the inspection, you could not provide records of CGMP training.\nIn your response, you state a consultant will assess your training procedure for general CGMP requirements and a suitable CGMP training program shall be developed.\nYour response is inadequate. You do not provide any immediate steps to address the training program to ensure all employees are adequately trained to complete CGMP activities. Nor do you commit to stop testing until employees can receive appropriate CGMP training.\nIn response to this letter, provide:\nA retrospective, independent review of all invalidated OOL\u002FOOS (including raw material, in-process, and release\u002Fstability testing) results for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOL\u002FOOS:\no Provide a list of all OOS and OOL results that were not investigated and your corresponding corrective actions including a reassessment of all instances to determine any additional action needed related to nonconforming results.\no For each OOL\u002FOOS include your CAPA and how you will ensure all OOS and OOL results will be investigated and communicated in a timely manner to your customer(s) on the certificate of analysis for appropriate follow up.\no Determine whether the scientific justification and evidence relating to the invalidated OOL\u002FOOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no An explanation for the discrepancy in the number of OOL and objectionable microorganism investigations that you provided to our investigator compared with the number that you provided to your customer, (b)(4).\nA comprehensive review and remediation plan for your OOL\u002FOOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Adequate scoping of each investigation and its CAPA\no Assurance that data, findings, and supporting documentation relating to any OOS\u002FOOL result are promptly conveyed to customers\no Revised OOL\u002FOOS investigation procedures with these and other remediations\nA description of how top management supports quality assurance and reliable test operations including, but not limited to, timely provision of resources to proactively address emerging quality issues and to assure a continuing state of control.\nDocumentation of training for all relevant personnel on revised policies, procedures, and other associated items.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you test. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nResponsibilities of Contract Testing Lab\nFDA considers contractors as extensions of the manufacturer’s own facility. Your failure to comply with CGMP may affect the quality, safety, and efficacy of the drugs you test for your customers. It is essential that you understand your responsibility to operate in full compliance with CGMP, and that you inform all your customers of any OOS results or significant problems encountered during the testing of these drugs.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm; you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003875820 and ATTN: Marva Taylor.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Microbiological Testing & Consulting, LLC","microbiological-testing-consulting-llc-720374-03162026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrobiological-testing-consulting-llc-720374-03162026","2026-10-26T08:09:24.793253+00:00","2026-03-31","720374","Ms. Lauren Szarzynski","2026-08-19T04:49:49.638+00:00","VIA EMAIL WITH READ RECEIPT","320-26-53","2026-03-16",{"id":304,"raw":305,"subject":104,"body_html":309,"body_text":310,"firm_name":311,"letter_id":312,"created_at":66,"fei_number":19,"letter_url":313,"updated_at":314,"action_type":22,"case_status":23,"posted_date":315,"marcs_cms_no":316,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":317,"body_fetched_at":318,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":319,"medical_device_id":19,"response_letter_date":19},544,[306,307,308,11,104,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-26T04:00:00Z\">09\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025\">Technological Medical Advancements LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Bruce R. Coren, DVM, MS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Technological Medical Advancements LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1601 Belvedere Rd Ste E-180\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Palm Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33406-1541\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bcoren@diowavelaser.com\"> bcoren@diowavelaser.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 712715\u003C\u002Fp>\u003Cp>September 26, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Coren:&nbsp;\u003C\u002Fp>\u003Cp>During an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS &amp; Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Technological Characteristics:\u003C\u002Fstrong> Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “\u003Cem>all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment\u003C\u002Fem>.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\u003C\u002Fp>\u003Cp>\u003Cem>o\u003C\u002Fem>&nbsp;\u003Cem> “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>As shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\u003C\u002Fp>\u003Cp>\u003Cstrong>Intended Use:\u003C\u002Fstrong>\u003Cbr>Generic devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\u003C\u002Fp>\u003Cp>\u003Cem>o &nbsp;“a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“treatment of various pathologies, including those refractive to traditional therapy”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”&nbsp;&nbsp;\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Further, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\u003C\u002Fp>\u003Cp>\u003Cem>“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer \u003Cstrong>(b)(4)\u003C\u002Fstrong> and your contract service firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by Section 3 of your procedure. Additionally, no \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\u003C\u002Fp>\u003Cp>B. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\u003C\u002Fp>\u003Cp>C. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\u003C\u002Fp>\u003Cp>i. &nbsp;Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\u003C\u002Fp>\u003Cp>ii. &nbsp;The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W. No evaluation on the potential need to submit a new premarket application was performed.\u003C\u002Fp>\u003Cp>iii. &nbsp;Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>. ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software (\u003Cstrong>(b)(4)\u003C\u002Fstrong> for 250 WLS, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for 100 WLS), as well as an identified power increase for the Diowave laser systems from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W were not available for review during the inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\u003C\u002Fp>\u003Cp>A. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\u003C\u002Fp>\u003Cp>B. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated \u003Cstrong>(b)(4)\u003C\u002Fstrong> servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\u003C\u002Fp>\u003Cp>A. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\u003C\u002Fp>\u003Cp>B. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\u003C\u002Fp>\u003Cp>&nbsp; i. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\u003Cbr>&nbsp; ii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\u003Cbr>&nbsp; iii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\u003C\u002Fp>\u003Cp>This FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identifier Regulation (UDI) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>A follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Bruce R. Coren, DVM, MS\n\nRecipient Title\n\nChief Executive Officer\n\nTechnological Medical Advancements LLC\n\n1601 Belvedere Rd Ste E-180\n\nWest Palm Beach, FL 33406-1541\n\nUnited States\n\nbcoren@diowavelaser.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712715\nSeptember 26, 2025\nDear Dr. Coren:\nDuring an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nFDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS & Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\nTechnological Characteristics: Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\no “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\no “Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\no “The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\nAs shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\nIntended Use:\nGeneric devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\no “a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\no “treatment of various pathologies, including those refractive to traditional therapy”\no “Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”\no “This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\no “peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\no “Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\no “Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\no “results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\nFurther, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\n“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\nYour firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\nA. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer (b)(4) and your contract service firm (b)(4), as required by Section 3 of your procedure. Additionally, no (b)(4) evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\nB. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\nC. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, (b)(4), responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\ni. Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\nii. The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from (b)(4)W to (b)(4)W. No evaluation on the potential need to submit a new premarket application was performed.\niii. Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “(b)(4). ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software ((b)(4) for 250 WLS, (b)(4) for 100 WLS), as well as an identified power increase for the Diowave laser systems from (b)(4)W to (b)(4)W were not available for review during the inspection.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, (b)(4), you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\nA. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\nB. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated (b)(4) servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\n3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\nA. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\nB. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\ni. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\nii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\niii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\nThis FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least (b)(4). Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\nUnique Device Identifier Regulation (UDI) Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\nSpecifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\nA follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Technological Medical Advancements LLC","technological-medical-advancements-llc-712715-09262025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025","2026-10-26T08:10:10.367898+00:00","2025-10-07","712715","Dr. Bruce R. Coren, DVM, MS","2026-08-19T16:15:16.641+00:00","2025-09-26",{"id":321,"raw":322,"subject":327,"body_html":328,"body_text":329,"firm_name":330,"letter_id":331,"created_at":332,"fei_number":19,"letter_url":333,"updated_at":334,"action_type":22,"case_status":23,"posted_date":335,"marcs_cms_no":336,"product_type":202,"closeout_date":19,"issuing_office":326,"recipient_name":337,"body_fetched_at":338,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":339,"medical_device_id":19,"response_letter_date":19},2795,[323,324,325,326,327,13,13,13],"\u003Ctime datetime=\"2022-03-28T14:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-24T04:00:00Z\">03\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-biological-laboratories-inc-627062-03242022\">Applied Biological Laboratories Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Latefi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Applied Biological Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>760 Parkside Ave., 317\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11226\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mlatefi@appliedbioinc.com\"> mlatefi@appliedbioinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date: March 24, 2022\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biovanta.com and http:\u002F\u002Fwww.appliedbioinc.com in February and March 2022; the Federal Trade Commission (FTC) also reviewed these websites in March 2022. The FDA has observed that your website, https:\u002F\u002Fwww.biovanta.com, offers “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. We also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc where you direct consumers to your website, https:\u002F\u002Fwww.appliedbioinc.com, which directs consumers to https:\u002F\u002Fwww.biovanta.com to purchase your products. Based on our review, “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims, including on your websites, that establish the intended use of your products and misleadingly represents them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“In conclusion, the scientific studies demonstrate that the active ingredients in Biovanta help\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>reduce the inflammation that causes upper respiratory infections, including COVID-19, while leading brands, which are designed to mask symptoms, do more harm than good.” [from your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall\u002Fthe-science-behind-biovanta-cold-cough-and-sore-throatotc-medicine-scientifically-proven-safer-and-more-effective]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Applied Biological Laboratories… launched Biovanta… Biovanta is proven superior to other\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>leading products… in third-party, blind, placebo-controlled laboratory studies. The scientific\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>publication titled ‘Rational drug design for sore throat – An aspirin-based treatment that addresses\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>bradykinin-induced inflammation’ explains the studies in more detail. According to the publication,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Biovanta modulates cytokines and strengthens the respiratory lining. Key inflammatory molecules\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>studied include bradykinin, which is implicated in the cytokine storm associated with COVID-19 and\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>other serious upper respiratory diseases… Applied Biological Laboratories Inc. is a New York based\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>biotechnology company committed to the research, development, and manufacturing of\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>drugs and therapies for respiratory diseases such as rhinovirus, influenza, coronavirus (including COVID-19), adenovirus, others.” [from the December 3, 2020 article as provided by you to PRNewswire,\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fbiovanta--the-only-100-natural-safeand-effective-over-the-counter-drug-for-cough-cold-and-sore-throat-301185288.html and to which you directly link from your May 20, 2021 post entitled “Biovanta: The only 100% natural, safe and effective over-the-counter drug for cough, cold and sore throat” on your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Just published the first scientific paper to finally address what works for sore throat, also to prevent a #BradykininStorm, treat #COVID_19 #COVID19 #SARSCoV2 symptoms and prevent #AntibioticResistance.” This is followed by a link to an abstract of your firm’s study entitled “Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin induced inflammation,” which mentions Biovanta. [from a November 8, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Despite my best efforts of trying to avoid getting sick during this pandemic, three days ago I got diagnosed with COVID 19. I had all the symptoms. I had a fever, I had a sore throat. My friend recommended me this product when told them that I was quarantining. It’s called Biovanta. It’s all natural. I got it from my local CVS and it’s a two step spray. I immediately noticed that it just like cleared my airways and I could take a deep breath.” [from a video called “Biovanta really helped me feel better!” you posted on your www.amazon.com Biovanta Throat Spray product page]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“More evidence that respiratory diseases should be treated in the nose and throat! https:\u002F\u002Flnkd.in\u002FdrSQX38N #biovanta #science #covid” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Study shows use of low-dose aspirin may prevent and shorten the duration of COVID-19 infection. More reasons to love our active ingredient. #science #covidー19 #innovation #health #aspirin #biovanta https:\u002F\u002Flnkd.in\u002Feu3bm23K” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Hey guys, so despite my best efforts of trying to avoid getting sick during this pandemic… by the time I came home I just started feeling really bad, tired, with a sore throat… noticed a dry cough and a sore throat… fever, I had a sore throat, I had a body aches and chills. I’m so excited that I found this product called Biovanta. It’s all natural which is awesome. I started seeing results immediately. And they deliver a really strong, really fast effective relief. The next day I felt 100%. The recovery was quick. It is phenomenal. Probably gonna get more of these and send them to my family and friends. I hope everyone stays safe out there and if anyone else is sick, I hope you feel better soon.” [from a video on your webpage https:\u002F\u002Fbiovanta.com\u002Fcollections\u002Fall-products and the YouTube video posted on December 18, 2020 on your Biovanta channel located at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=tIewyLf1EXo]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>FTC Cease and Desist Demand: \u003C\u002Fstrong>In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> According to the Cision PRNewswire Client Terms &amp; Conditions a “Client” purchases services from Cision and\u002For its affiliates and “[f]or each Release, Client shall indicate, in writing, (i) the name of the issuer of the Release. . . which name shall be displayed to the public as the source of the Release. . .” available at https:\u002F\u002Fwww.cision.com\u002Flegal\u002Fprnewswire-customer-terms-landing-page\u002F#info2.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Latefi\n\nApplied Biological Laboratories Inc.\n\n760 Parkside Ave., 317\n\nBrooklyn, NY 11226\n\nUnited States\n\nmlatefi@appliedbioinc.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: March 24, 2022\n\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biovanta.com and http:\u002F\u002Fwww.appliedbioinc.com in February and March 2022; the Federal Trade Commission (FTC) also reviewed these websites in March 2022. The FDA has observed that your website, https:\u002F\u002Fwww.biovanta.com, offers “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. We also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc where you direct consumers to your website, https:\u002F\u002Fwww.appliedbioinc.com, which directs consumers to https:\u002F\u002Fwww.biovanta.com to purchase your products. Based on our review, “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims, including on your websites, that establish the intended use of your products and misleadingly represents them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“In conclusion, the scientific studies demonstrate that the active ingredients in Biovanta help reduce the inflammation that causes upper respiratory infections, including COVID-19, while leading brands, which are designed to mask symptoms, do more harm than good.” [from your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall\u002Fthe-science-behind-biovanta-cold-cough-and-sore-throatotc-medicine-scientifically-proven-safer-and-more-effective]\n\n“Applied Biological Laboratories… launched Biovanta… Biovanta is proven superior to other leading products… in third-party, blind, placebo-controlled laboratory studies. The scientific publication titled ‘Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin-induced inflammation’ explains the studies in more detail. According to the publication, Biovanta modulates cytokines and strengthens the respiratory lining. Key inflammatory molecules studied include bradykinin, which is implicated in the cytokine storm associated with COVID-19 and other serious upper respiratory diseases… Applied Biological Laboratories Inc. is a New York based biotechnology company committed to the research, development, and manufacturing of drugs and therapies for respiratory diseases such as rhinovirus, influenza, coronavirus (including COVID-19), adenovirus, others.” [from the December 3, 2020 article as provided by you to PRNewswire,4 https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fbiovanta--the-only-100-natural-safeand-effective-over-the-counter-drug-for-cough-cold-and-sore-throat-301185288.html and to which you directly link from your May 20, 2021 post entitled “Biovanta: The only 100% natural, safe and effective over-the-counter drug for cough, cold and sore throat” on your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall]\n\n“Just published the first scientific paper to finally address what works for sore throat, also to prevent a #BradykininStorm, treat #COVID_19 #COVID19 #SARSCoV2 symptoms and prevent #AntibioticResistance.” This is followed by a link to an abstract of your firm’s study entitled “Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin induced inflammation,” which mentions Biovanta. [from a November 8, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs]\n\n“Despite my best efforts of trying to avoid getting sick during this pandemic, three days ago I got diagnosed with COVID 19. I had all the symptoms. I had a fever, I had a sore throat. My friend recommended me this product when told them that I was quarantining. It’s called Biovanta. It’s all natural. I got it from my local CVS and it’s a two step spray. I immediately noticed that it just like cleared my airways and I could take a deep breath.” [from a video called “Biovanta really helped me feel better!” you posted on your www.amazon.com Biovanta Throat Spray product page]\n\n“More evidence that respiratory diseases should be treated in the nose and throat! https:\u002F\u002Flnkd.in\u002FdrSQX38N #biovanta #science #covid” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\n\n“Study shows use of low-dose aspirin may prevent and shorten the duration of COVID-19 infection. More reasons to love our active ingredient. #science #covidー19 #innovation #health #aspirin #biovanta https:\u002F\u002Flnkd.in\u002Feu3bm23K” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\n\n“Hey guys, so despite my best efforts of trying to avoid getting sick during this pandemic… by the time I came home I just started feeling really bad, tired, with a sore throat… noticed a dry cough and a sore throat… fever, I had a sore throat, I had a body aches and chills. I’m so excited that I found this product called Biovanta. It’s all natural which is awesome. I started seeing results immediately. And they deliver a really strong, really fast effective relief. The next day I felt 100%. The recovery was quick. It is phenomenal. Probably gonna get more of these and send them to my family and friends. I hope everyone stays safe out there and if anyone else is sick, I hope you feel better soon.” [from a video on your webpage https:\u002F\u002Fbiovanta.com\u002Fcollections\u002Fall-products and the YouTube video posted on December 18, 2020 on your Biovanta channel located at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=tIewyLf1EXo]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 According to the Cision PRNewswire Client Terms & Conditions a “Client” purchases services from Cision and\u002For its affiliates and “[f]or each Release, Client shall indicate, in writing, (i) the name of the issuer of the Release. . . which name shall be displayed to the public as the source of the Release. . .” available at https:\u002F\u002Fwww.cision.com\u002Flegal\u002Fprnewswire-customer-terms-landing-page\u002F#info2.","Applied Biological Laboratories Inc.","applied-biological-laboratories-inc-627062-03242022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-biological-laboratories-inc-627062-03242022","2026-10-26T08:07:56.783818+00:00","2022-03-28","627062","Mr. Michael Latefi","2026-08-20T02:04:41.098+00:00","2022-03-24",{"id":341,"raw":342,"subject":61,"body_html":347,"body_text":348,"firm_name":349,"letter_id":350,"created_at":332,"fei_number":19,"letter_url":351,"updated_at":352,"action_type":22,"case_status":23,"posted_date":353,"marcs_cms_no":354,"product_type":71,"closeout_date":19,"issuing_office":346,"recipient_name":355,"body_fetched_at":356,"delivery_method":357,"recipient_title":19,"reference_number":19,"action_taken_date":358,"medical_device_id":19,"response_letter_date":19},2854,[343,344,345,346,128,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022\">Smart Surgical, Inc dba Burst Biologics\u003C\u002Fa>","Office of Biological Products Operations – Division 2","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher D. Jones\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smart Surgical, Inc dba Burst Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3501 W. Elder St., Ste. 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 21-614361]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jones:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Burst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\n\n\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\u003C\u002Fp>\n\n\u003Cp>a. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>b. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes that up to and including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is &lt;1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a \u003Cem>Paenibacillus\u003C\u002Fem> species, \u003Cem>Bacillus\u003C\u002Fem> non-anthracis, \u003Cem>Kocuria rhizophila\u003C\u002Fem>,&nbsp;\u003Cem>Staphylococcus hominis\u003C\u002Fem>, and \u003Cem>Micrococcus luteus\u003C\u002Fem>) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP &lt;71&gt;, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\u003Cbr>\n\u003Cbr>\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher D. Jones\n\nRecipient Title\n\nChief Executive Officer\n\nSmart Surgical, Inc dba Burst Biologics\n\n3501 W. Elder St., Ste. 104\n\nBoise, ID 83705\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2022\n\n[OBPO 21-614361]\n\nDear Mr. Jones:\n\nDuring an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBurst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\n\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in (b)(4), an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\n\n2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\n\na. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\n\nb. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate1. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for (b)(4) days.\n\n3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\n\na. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately (b)(4) units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\n\nb. Your environmental monitoring procedure describes that up to and including (b)(4) colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is \u003C1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and (b)(4) for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a Paenibacillus species, Bacillus non-anthracis, Kocuria rhizophila, Staphylococcus hominis, and Micrococcus luteus) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv.\n\nIn addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP \u003C71>, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\n\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc\n\n(b)(6)\n\n_______________________________\n\n1 We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.","Smart Surgical, Inc dba Burst Biologics","smart-surgical-inc-dba-burst-biologics-614361-02022022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022","2026-10-26T08:09:59.293166+00:00","2022-02-22","614361","Mr. Christopher D. Jones","2026-08-20T02:09:59.584+00:00","VIA UNITED PARCEL SERVICE","2022-02-02",{"id":360,"raw":361,"subject":61,"body_html":365,"body_text":366,"firm_name":367,"letter_id":368,"created_at":18,"fei_number":19,"letter_url":369,"updated_at":370,"action_type":22,"case_status":23,"posted_date":371,"marcs_cms_no":19,"product_type":71,"closeout_date":19,"issuing_office":59,"recipient_name":372,"body_fetched_at":373,"delivery_method":74,"recipient_title":19,"reference_number":374,"action_taken_date":375,"medical_device_id":19,"response_letter_date":19},1305,[362,363,364,59,128,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-28T04:00:00Z\">06\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo\">Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 676984\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mesfin Mengesha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>880 Harbour Way S., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 28, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mengesha:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\u003C\u002Fp>\n\n\u003Cp>Human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Your products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\u003C\u002Fp>\n\n\u003Cp>Your products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Therefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\u003C\u002Fp>\n\n\u003Cp>Be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\u003C\u002Fp>\n\n\u003Cp>Your CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> For example, you failed to determine as ineligible \u003Cstrong>(b)(4)\u003C\u002Fstrong> deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 \u003Cem>Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs)\u003C\u002Fem> (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of \u003Cem>Mycobacterium tuberculosis\u003C\u002Fem> infections. It appears this is a systemic issue not limited to these \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors or products because this violation resulted from you following your SOP-0006 \u003Cem>Donor Eligibility Determination Criteria\u003C\u002Fem>, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\u003C\u002Fp>\n\n\u003Cp>We have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\u003C\u002Fp>\n\n\u003Cp>In your October response, you provided your revised procedure, \u003Cem>SOP-006 Donor Eligibility Determination Criteria\u003C\u002Fem> (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\u003C\u002Fp>\n\n\u003Cp>This donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\u003C\u002Fp>\n\n\u003Cp>Your CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example,\u003C\u002Fp>\n\n\u003Cp>a. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required \u003Cstrong>(b)(4)\u003C\u002Fstrong> donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> OVM donor batches failed to meet your acceptance criteria, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> donor batches failed to meet your acceptance criteria for sterility testing.\u003C\u002Fp>\n\n\u003Cp>b. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\u003C\u002Fp>\n\n\u003Cp>Based on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>b. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\u003C\u002Fp>\n\n\u003Cp>c. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\n\n\u003Cp>In your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\u003C\u002Fp>\n\n\u003Cp>Please also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations - Division 2\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\n\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 676984\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMesfin Mengesha\n\nRecipient Title\n\nChief Executive Officer\n\nBerkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.\n\n880 Harbour Way S., Suite 100\n\nRichmond, CA 94804\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nJune 28, 2024\n\nDear Mr. Mengesha:\n\nDuring an inspection of your firm, Berkeley Biologics, LLC, (operating during the inspection as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.), located at 880 Harbour Way S., Suite 100, Richmond, CA 94804, conducted between September 05, 2023 and September 25, 2023, the United States Food and Drug Administration (FDA) documented your manufacture of viable bone matrix products derived from human bone tissue and marketed as Viable Bone Matrix (VBM), Fiber Viable Bone Matrix (FVBM), Cellular Fiber Matrix (CFM)\u002FExcel Viable Bone Matrix (EFM),1 and Osteo Viable Bone Matrix (OVM). You have distributed these products throughout the United States to medical facilities. You intend these products to be used in orthopedic or reconstructive bone grafting procedures for bone repair and regeneration, and you purport them to be sterile.\n\nHuman cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. § 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and\u002For the Public Health Service Act (PHS Act) [42 U.S.C. § 262], and are subject to additional regulation, including appropriate premarket review.\n\nYour products do not qualify for any exception in 21 CFR 1271.15, and your VBM, CFM\u002FEFM, and OVM products fail to meet all the criteria in 21 CFR 1271.10(a). Specifically, VBM, CFM\u002FEFM, and OVM fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of cartilage relating to its utility to perform its load-bearing and other physical functions, which generally include firmness, smoothness, flexibility, and resistance to deformation.\n\nYour products also fail to meet the criterion under 21 CFR 1271.10(a)(3) that the manufacture of the HCT\u002FP does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent. Your VBM, CFM, and OVM products are a combination of bone (cancellous and cortical) and another article, (b)(4).\n\nTherefore, these three products – VBM, CFM\u002FEFM, and OVM – are not regulated solely under section 361 of the PHS Act [42 U.S.C. § 264] and the regulations in 21 CFR Part 1271. Because these products do not meet all the criteria in 21 CFR 1271.10(a), and you do not qualify for any exception in 21 CFR 1271.15, these products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)].\n\nBe advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR 312]. None of your products are the subject of an approved BLA, nor is there an IND in effect for any of them. Based on our review, these products are unapproved new drugs that you are introducing or delivering for introduction into interstate commerce in violation of sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented significant deviations from current good tissue practice (CGTP) requirements, including deviations from 21 CFR 1271, for FVBM and OVM. Upon further review of information collected during the inspection, FDA also identified significant deviations from current good manufacturing practice (CGMP) requirements for VBM, CFM\u002FEFM, and OVM, including section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP requirements, your VBM, CFM\u002FEFM, and OVM drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)], your introduction or delivery for introduction into interstate commerce of these three drug products is a prohibited act.\n\nYour CGTP deviations for your FVBM and OVM products manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. For example, you failed to determine as ineligible (b)(4) deceased donors who have a documented medical diagnosis of sepsis. As discussed in the 2007 Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT\u002FPs) (2007 DE Guidance), donor screening to reduce the risk of transmission of disease agents associated with sepsis is required. Tissues from these donors were manufactured into FVBM and OVM, and distributed for implantation into patients\u002Frecipients, some of which were associated with an outbreak of Mycobacterium tuberculosis infections. It appears this is a systemic issue not limited to these (b)(4) donors or products because this violation resulted from you following your SOP-0006 Donor Eligibility Determination Criteria, which does not require you to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, sepsis.\n\nWe have received and reviewed your written responses, dated October 14, 2023, and November 30, 2023, to FDA’s inspectional observations on the Form FDA-483. The corrective actions described in your response are not adequate to address the above noted violation that was on the FDA-483.\n\nIn your October response, you provided your revised procedure, SOP-006 Donor Eligibility Determination Criteria (as Attachment 2.2). Your “Donor Screening Guidance Document” in Attachment 2.2 and the revised sepsis algorithm in SOP-0006 do not determine as ineligible, donors who have a documented medical diagnosis of sepsis. Sepsis is a relevant communicable disease agent and disease (RCDAD) under 1271.3(r)(2), as described in the 2007 DE Guidance. Under 1271.75(d)(1), you must determine as ineligible a donor who is identified as having a risk factor for or clinical evidence of any RCDAD. You should revise Berkeley’s Donor Screening Guidance Document for sepsis and revise your sepsis algorithm in SOP-0006 so that these documents are compliant with 1271.75(d)(1).\n\nThis donor eligibility issue applies across your products, including those regulated solely under section 361 of the PHS Act. Based on information available to FDA, you have received tissues from at least (b)(4) donors who have sepsis documented in their medical records. We request that you provide us a list of all donors that have had risk factors for or clinical evidence of sepsis that you have determined to be eligible along with the products you have manufactured and distributed from these donors.\n\nYour CGMP deviations for VBM, CFM\u002FEFM, and OVM manufactured between January 2022 and June 2023, include, but are not limited to, the following:\n\n2. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example,\n\na. According to your Process Qualification Reports (dated January 17, 2017, March 16, 2020, and April 7, 2023), you only required (b)(4) donors to meet your process qualification acceptance criteria even if some donor batches in the validation\u002Fqualification failed to meet the criteria. For example, (b)(4) of (b)(4) OVM donor batches failed to meet your acceptance criteria, and (b)(4) of the (b)(4) donor batches failed to meet your acceptance criteria for sterility testing.\n\nb. You have not validated the manufacturing processes for VBM, CFM\u002FEFM, and OVM with respect to identity, strength, quality, and purity. Your Process Qualification Reports document product bioburden testing, sterility testing, environmental and personnel monitoring, and in some cases (b)(4) testing, as the only tests included in your acceptance criteria. These tests are inadequate to assure the identity, strength, quality, and purity of these products.\n\nBased on our review of the “retrospective validation addendums” you provided in your November 2023 response, you have not addressed the issues noted above. For example, your validations continue to focus on sterility assurance controls, rather than identity, strength, quality, and purity.\n\n3. Failure to have an adequate system necessary to prevent contamination or mix-ups during aseptic processing [21 CFR 211.42(c)(10)(iv)]. For example:\n\na. Your action limits for microbiological monitoring (i.e., active viable air and surface samples) within the critical area (i.e., inside the Biological Safety Cabinet (BSC)) were observed to be greater than (b)(4) colony forming units (CFUs). Such high numbers of microorganisms can contribute to product contamination and pose a potentially significant safety concern.\n\nb. You do not perform sampling of critical surfaces in the BSC for microorganisms in association with each production batch.\n\nc. Your personnel monitoring sample locations are inadequate for personnel performing aseptic processing. For example, your firm does not conduct personnel monitoring of the forearms\u002Fsleeves of operators working in the BSC where your products are aseptically processed.\n\n4. Failure to establish laboratory controls that include scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example:\n\na. You have not established scientifically sound and appropriate specifications and test procedures to assure that VBM, CFM\u002FEFM, and OVM conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing, which is inadequate to measure appropriate standards of identity, strength, quality, and purity.\n\nb. Sterility samples of VBM, CFM\u002FEFM, and OVM are frozen prior to sterility testing. Freezing product has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n\nIn your responses, you have committed to stopping the manufacture and distribution of all viable bone matrix products until, you state, you have met, “FDA’s standards for tissue processing validation.” However, you have not addressed the products manufactured under the violative conditions described above that remain on the market and available for implantation nor have you addressed the above CGMP violations. We acknowledge that the above CGMP violations were not included in the FDA-483; we expect you to address them in response to this letter.\n\nAdditionally, your response fails to address your failure to have an IND in effect to study your VBM, CFM\u002FEFM, and OVM products or your lack of an approved BLA to lawfully market these products.\n\nPlease also be advised that FDA has conducted a preliminary review of your HCT\u002FP, Fiber Viable Bone Matrix (FVBM). Based on the limited information available to FDA, we do not have a basis at this time for concluding that the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271 are met for Berkeley Biologics’ FVBM allogeneic HCT\u002FP.\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure that your establishment is in full compliance with applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you believe that your products are not in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion.\n\nYour response to this letter should be sent to the following address: Amy Graf, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive – Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations - Division 2\n\ncc:\n\n(b)(6), (b)(7)(C)\n\n____________________\n\n1 We note that the product name was changed from Excel Fiber Matrix to Cellular Fiber Matrix on April 21, 2023.","Berkeley Biologics, LLC, previously operating as Elutia, Inc. – Orthobiologics Business Unit, formerly Aziyo Biologics, Inc.","berkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fberkeley-biologics-llc-previously-operating-elutia-inc-orthobiologics-business-unit-formerly-aziyo","2026-10-26T08:08:03.464886+00:00","2024-08-27","Mesfin Mengesha","2026-08-19T23:52:08.617+00:00","OBPO 676984","2024-06-28",18,{"510k":378,"classification":379,"enforcement":380,"event":381,"event_backfill":382,"pma":383,"warning_letter":384},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]